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The participation of tRNAs in fundamental aspects of biology and disease ne-
cessitates an accurate, experimentally confirmed annotation of tRNA genes, and
curation of precursor and mature tRNA sequences. This has been challenging,
mainly because RNA secondary structure and nucleotide modifications, together
with tRNA gene multiplicity, complicate sequencing and read mapping efforts.
To address these issues, I developed hydro-tRNAseq, a method based on par-
tial alkaline RNA hydrolysis that generates fragments amenable for sequencing.
To identify transcribed tRNA genes, I further complemented this approach with
Photoactivatable Crosslinking and Immunoprecipitation (PAR-CLIP) of SSB/La, a
conserved protein involved in pre-tRNA processing. My results show that approxi-
mately half of all predicted tRNA genes are transcribed in human cells, suggesting
that the tRNA genomic space is more contracted than previously thought as a re-
sult of regulation of expression. I also report predominant nucleotide modification
sites, their order of incorporation, and identify tRNA leader, trailer and intron se-
quences. By using complementary sequencing-based methodologies I present a
human tRNA reference set, and determine expression levels of mature and pro-
cessing intermediates of tRNAs in human cells.
The technical advances provided by hydro-tRNAseq are applied towards the
molecular diagnosis of a genetic neurodevelopmental syndrome, caused by mu-
tations in the tRNA processing factor CLP1.
Finally, I harness this novel experimental and computational expertise towards
the identification of the endonuclease complex C3PO as a novel processing fac-
tor of human tRNAs. I carry out a transcriptome-wide analysis of C3PO targets,
identify its binding sites and motifs, and provide insights into its biochemical and
biological functions.
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Transfer RNAs are essential factors for the expression of genetic information, serv-
ing as the adaptor molecules that decode the genetic code during protein synthe-
sis [1], and are among the earliest studied non-coding RNA (ncRNA) non-coding
RNA molecules [2, 3]. The biological importance of tRNAs and their associated
proteins is underscored by the pathologic conditions that are related to aberra-
tions in their expression and function [4–7]. Despite their highly conserved par-
ticipation in the translational machinery, tRNAs have received new attention in
recent years in the context of codon-resolved translational control [8–13], and due
to the involvement of their metabolic byproducts in regulation and cross-talk with
processing and effector functions of other classes of non-coding RNAs (ncRNAs)
[14–18].
Nevertheless, the lack of reliable methods for tRNA quantification has ham-
pered such analyses, and necessitated the use of predicted tRNA gene copy
number as a surrogate index of expression [12, 19, 20]. This hinged on the
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assumption that predicted tRNA gene loci are all expressed constitutively and
equally, even though there has been experimental evidence against it [21]. Simi-
larly, experimental tRNA gene annotation in the past had to focus on human RNA
polymerase III (POLR3) chromatin immunoprecipitation sequencing (ChIP-seq)
[22–24] or hybridization-based approaches [25, 26]. The former, however, were
impeded by their restricted genomic resolution and the assumption that POLR3
binding always leads to productive tRNA expression followed by complete pro-
cessing, while the latter fell short of providing absolute counts and did not address
the discovery of new transcripts and genes, assuming also normal hybridization
rules for modified nucleosides.
An improvement in tRNA quantification has arisen from recent efforts that em-
ployed modification-reverting enzymes prior to sequencing, in order to minimize
stalling of reverse transcriptase at modified sites [27, 28]. However, an extensive
annotation of human genes and transcripts was foregone because the focus was
either on mature tRNAs only [28] or on tRNA fragments not inclusive of full-length
precursor tRNA (pre-tRNA) transcripts [27]. Thus, to-date an experimentally vali-
dated list of curated mature and pre-tRNA sequences and annotating tRNA genes
in human cells is still missing.
To address this lack of experimentally-validated tRNA reference, I combined
complementary high-throughput techniques for obtaining the sequence composi-
tion and abundance of tRNAs in human cells.
1.2 tRNA biogenesis
tRNA genes are transcribed by POLR3 that uses promoters internal to the DNA
sequence of the tRNA gene (tDNA), resulting in a primary transcript with a 5’
3
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Figure 1.1: Overview of tRNA biogenesis and processing. tRNAs are tran-
scribed by POLR3. If present, tRNA introns are removed by the tRNA splicing
complex (TSEN and CLP1), and mature halves are ligated by the tRNA ligase
(RTCB). Pre-tRNA leaders are trimmed by the RNase P complex, and 3’ trailer
by ELAC2. The 3’ terminal CCA tail is added by TRNT1. tRNAs are further mod-
ified by nucleoside editing in the nucleus and the cytoplasm, are aminoacylated
by cognate tRNA synthetases and are presented to the ribosome by translation
factors.
triphosphate. In humans, a minority of tRNA transcripts harbor introns (see sec-
tion 3.6). A dedicated tRNA splicing complex composed of core and accessory
proteins carries out tRNA splicing [29–33]. Pre-tRNAs comprise the mature tRNA
sequence, and 5’ leader and 3’ trailer extensions, which are trimmed in a coordi-
nated manner by endonucleases and other processing factors. The ribonucleopro-
tein (RNP) complex RNase P removes the 5’ leaders, leaving a 5’ monophospahte,
and possibly ELAC2, the human homolog of tRNase Z trims the 3’ trailer, leaving
4
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a 3’ hydroxyl (OH). Next, the universally conserved 3’ terminal CCA tail is added
by the tRNA nucleotidyl transferase 1 (TRNT1), and acts as the acceptor of the
amino acid. tRNAs are further modified by chemical nucleotide modifications (3.5),
exported from the nucleus to the cytoplasm where they can undergo further mod-
ifcations, are aminoacylated with their cognate amino acid by aminoacyl tRNA
synthetases, and are finally presented to the ribosome by translation factors to
participate in protein synthesis (Fig. 1.1)[34–36]. Mature tRNAs adopt a clover-
leaf secondary and L-shaped tertiary structure (Fig. 1.2)
Although these processes allow for multiple levels of regulation, variation in
tRNA expression across tissues or between normal and pathologic conditions has
not been studied extensively, mainly for two reasons. First, until recently there
was the assumption that their essentiality obviated a need for any specialized
transcriptional or post-transcriptional control. Second, the lack of an extensively
curated and experimentally validated tRNA profile prevented quantitative and sys-
tematic studies. Nevertheless, it is now clear that the expression of tRNAs can
be dynamic and can indeed exhibit tissue specificity [21, 37]. Importantly, abnor-
mal tRNA expression levels have been correlated and causally associated with
pathologic conditions, such as cancer [21, 26].
1.3 tRNA sequencing
Their complex biogenesis and processing pathway adds multiple layers of diffi-
culty to the analysis of tRNAs. Obtaining data for tRNAs is hindered by multiple
obstacles:
i) sequencing of tRNAs is technically arduous due to their relatively small size,
and their stable structure that impedes enzymes used in cDNA library prepa-
5
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Figure 1.2: tRNA structure. (A) tRNA transcripts, such as the phenylalanine
tRNA shown here, adopt the typical cloverleaf secondary structure, which in turns
adopts an L-shaped tertiary structure as shown in (B). The structurally conserved
stems and stemloops are indicated in (A), color-coded, and their coordinates are
reflected in the 3-dimensional structure in B (PDB 1EHZ).
rations, such as RNA ligases and reverse transcriptase (RT)
ii) numerous (>100) tRNA pseudogenes are interspersed in the human genome
[38, 39]
iii) all tRNAs undergo extensive post-transcriptional processing (see 1.1), while
some involve extra processing steps (intron removal, addition of a 5’ guano-
sine to all histidine tRNAs [40])
iv) tRNAs are subjected to extensive chemical modifications on numerous nucle-
osides, which lead to mismatches upon the reverse transcription step of the
RNA cloning protocols [41, 42]. Some modifications are universally conserved
and required for proper tRNA function (e.g. adenosine to inosine deamination
at the wobble position of the anticodon and methylation of adenosine in the
TΨC loop) [41, 43]. Since alignment algorithms cannot tolerate multiple mis-
matches, it is likely that significant numbers of tRNA reads are excluded even
6
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if non-default mapping parameters are used.
v) tRNA isoacceptors share a large degree of sequence similarity that makes the
distinction between alternative isoacceptors and editing products equivocal.
vi) eukaryotic cells harbor two distinct populations of tRNAs, nuclear and mito-
chondrial, whose length, structure, genomic organization, and processing dif-
fer considerably, and thus call for customized annotation procedures.
Owing to all these hurdles, the normal genetic makeup and variation of the
tRNA population in human cells has not been probed adequately with RNA se-
quencing (RNA-seq) tools. Instead, information about tRNA sequences and genes
comes from bioinformatic predictions [38, 39]. Such approaches take into account
base-pair covariation, secondary structure predictions of the classical cloverleaf
fold of tRNAs, and the tRNA promoter and termination architecture, and scan the
human genome in order to identify sequences that are likely to obtain the typical
tRNA structure. These analyses have resulted in the most comprehensive stan-
dard for whole-genome, predictive annotation of tRNAs so far, and the sequences
they have predicted have been used extensively as bona fide tRNAs.
1.4 Previous efforts for genome-wide tRNA annota-
tion
Even though no direct and rigorous experimental validation of tRNA sequences
has been carried out, there has been indirect experimental evidence for tRNA
expression:
i) ChIP-seq studies, focusing on the occupancy of genomic locations by POLR3
and/or its transcription factors [22–24]
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ii) tRNA microarrays, using the predicted tRNA sequences as the reference for
the creation of array probes [25]
These methods, though, have several limitations. ChIP-seq, for example, uses
chromatin occupancy as a proxy for productive RNA synthesis. Conversely, tRNA
microarrays have limited sensitivity and specificity thresholds due to off-target hy-
bridization that is potentiated by nucleoside modifications, while their dynamic
range is considerably narrower than RNA-seq. Finally, neither method is appro-
priately equipped to determine definitively pre-tRNAs or their transcription start
and termination sites. This is an important limitation, as pre-tRNA fragments have
been associated with neurodegenerative diseases [44–46].
1.5 Small RNA sequencing protocol
In order to obtain RNA-seq reads, I decided to first apply the well established pro-
tocol for sequencing small RNAs, developed in the Tuschl lab [47] (Fig. 1.3). The
experimental procedure takes advantage of the 5’ monophosphate (p) and 3’ OH
groups present in small RNAs, such as microRNAs (miRNAs), in order to enrich
for such RNA species over other abundant RNA molecules. The use of a truncated
and mutated RNA ligase (T4 Rnl2(1-249)K227Q) that requires 5’ preadenylated
adapter (App-(5’)-adapter) prevents on one hand the formation of secondary, cir-
cularized byproducts, and allows on the other for exclusive ligation at the 3’ end of
the target RNA. Rnl1 is used to ligate an adapter with a different sequence at the
5’ end, by activating the 5’ monophosphate of the small RNA. cDNA is obtained by
RT and amplified at non-saturated levels by PCR. The derived small RNA cDNA
library is submitted to high-throughput sequencing on Illumina instruments us-
ing sequencing primer sites present in the adapter sequences. The different se-
8
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quences of the 3’ and 5’ adapters preserve the strandedness of the original RNA
sequence, enhancing ncRNA discovery and curation. Adding short (5-nt) barcode
sequences at the 3’ adapter also allows for pooling of several multiplexed samples,
reducing costs, processing time, and batch variability.
Figure 1.3: Small RNA sequencing protocol. Schematic overview of the con-
ventional small RNA sequencing protocol, as it has been described previously
[47]
Even though the utility of this protocol has been documented for the discovery
and quantification of miRNAs, it was reasonable to apply towards tRNA sequenc-
ing because:
i) tRNAs, which are on average 75 nucleotides (nts) long, are closer in length
than most other highly abundant ncRNAs (typically longer than 150 nts)
9
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ii) mature tRNAs and miRNAs both have a 5’ monophosphate and 3’ OH, which
are employed at different steps of library preparation
The application of this protocol for tRNA sequencing, though, resulted in RNA-
seq datasets with only 2% tRNA content, with an average length of 59 nts (Table.
1.1). These suggested that tRNAs were refractory to the small RNA sequencing
protocol, and necessitated the development of a novel sequencing method.
Table 1.1: RNA types recovered by small RNA sequencing protocol. Per-
centage of reads mapped to indicated ncRNA type over total depth of library, and
mean length of reads mapped to RNAs of each type are shown. snRNA: small
nuclear RNA; snoRNA: small nucleolar RNA; repeat: repetitive DNA sequence;
miscRNA: all other ncRNAs.
RNA type % Total reads Mean length (nt)
rRNA 35.8% 60.5
no match 24.1% 76.2










In order to overcome the problems associated with tRNA sequencing, I tried to
identify the minimal number of simplest steps that could tackle the maximal num-
ber of problems. Thus, I isolated 60-100 nt-sized total RNA from human embryonic
kidney cells 293 (HEK293) cells, comprising both pre- and mature tRNAs, but be-
ing devoid of most other abundant RNAs and short tRNA turnover products [16].
Full-length tRNAs have thermodynamically stable secondary and tertiary struc-
tures and are heavily modified by RNA editing, all of which compromise RT and
RNA-seq analysis. To overcome these problems, I implemented a limited alkaline
hydrolysis step. I reasoned that hydrolysis would generate shorter RNA fragments
less prone to adopt stable structures, and would also reduce the number of modi-
fied nucleosides per sequenced fragment.
The value of the latter effect becomes apparent if one performs the following
thought experiment. Let us assume that the probability of an RT "problem" (stall,
drop or misincorporation) is the same for all modifications (p). The compound
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probability of RT stalling, dropping or misincorporating a nucleoside in a given
sequence is given by the product of any of these events happening at a given
modified position, and is equal to:
P = pn (2.1)
where n = number of modified nucleosides affecting RT. Given that full length
tRNAs are longer than the hydrolysis-derived fragments, and modifications are
usually distributed over the loops of the tRNA (Fig. 1.2 and Fig. 3.6), then
nfull−length ≥ nfragment (2.2)
and therefore:
Pfull−length ≥ Pfragment (2.3)
and the probability of sequencing through an RNA fragment (1 − p):
1 − Pfull−length ≤ 1 − Pfragment (2.4)
In addition to increasing read-through by RT, the reduced frequency of modified
nucleosides per sequenced fragment, also improves mapping efforts by reducing
the number of mismatches per sequenced read. Furthermore, basic conditions
also cleave the aminoacyl-tRNA bond, freeing the 3’ terminal hydroxyl group re-
quired for 3’ adapter ligation during RNA cDNA library preparation. Thus, I antic-
ipated that collectively these effects would yield RNA sequences more amenable
to small RNA cDNA library preparation and deep sequencing than the refrac-
tory tRNAs. Indeed this approach increased the tRNA read content to >40% in
12
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Figure 2.1: Hydro-tRNAseq experimental and bioinformatic pipeline for
tRNA annotation and reference transcript curation by hydro-tRNAseq. (A)
tRNAs and pre-tRNAs were size-selected from HEK293 total RNA and subjected
to limited alkaline hydrolysis, followed by dephosphorylation, rephosphorylation
and conventional small RNA sequencing as described previously (Hafner et al.,
2012). (B) An iterative mapping and annotation protocol was used to first anno-
tate and curate fully processed and nucleotide-modified mature tRNAs. Leftover
reads that spanned the mature-precursor junctions were used to identify tran-
scribed tRNA genes.
our deepest dataset (Table 2.1). We named this procedure hydro-tRNAseq (Fig.
2.1A).
Encouraged by the preliminary performance of the protocol, I set out to obtain
a curated list of human nuclear and mitochondrial tRNAs, their genomic loci, and




Table 2.1: Hydro-tRNAseq reads per RNA type. Reads assigned to each RNA
type following hierarchical annotation are shown. Reads with no (d0), one (d1) or
two (d2) mismatches compared to reference are shown. Hydro-tRNAseq enriches
for nuclear (44%) and mitochondiral (15%) tRNAs.










tRNA 41,880,208 9,444,737 2,814,103 54,139,048 44% 47% 47% 77% 17% 5%
rRNA 18,825,243 4,317,680 1,222,652 24,365,575 20% 21% 21% 77% 18% 5%
mt tRNA 15,254,805 2,976,430 736,595 18,967,830 15% 17% 17% 80% 16% 4%
snoRNA 8,126,590 1,635,120 388,833 10,150,543 8% 9% 9% 80% 16% 4%
mRNA 951,538 231,248 89,536 1,272,322 1% 1% 1% 75% 18% 7%
mRNA gene 828,458 229,342 150,541 1,208,341 1% 1% 1% 69% 19% 12%
snRNA 773,703 169,800 43,861 987,364 1% 1% 1% 78% 17% 4%
pre-tRNA 529,077 247,304 146,557 922,938 1% 1% 1% 57% 27% 16%
genome 327,950 114,402 153,951 596,303 0% 1% 0% 55% 19% 26%
mt rRNA 363,913 86,271 24,813 474,997 0% 0% 0% 77% 18% 5%
scRNA 339,135 91,056 27,098 457,289 0% 0% 0% 74% 20% 6%
marker 113,303 52,725 32,143 198,171 0% 0% 0% 57% 27% 16%
rRNA prec 106,373 49,811 12,589 168,773 0% 0% 0% 63% 30% 7%
bacterial 31,724 38,555 52,354 122,633 0% 0% 0% 26% 31% 43%
mt mRNA 47,466 12,816 4,887 65,169 0% 0% 0% 73% 20% 7%
lincRNA gene 35,934 10,686 9,516 56,136 0% 0% 0% 64% 19% 17%
mt genome 17,990 14,749 20,379 53,118 0% 0% 0% 34% 28% 38%
miRNA 5,425 7,443 38,348 51,216 0% 0% 0% 11% 15% 75%
lincRNA 26,713 6,474 1,460 34,647 0% 0% 0% 77% 19% 4%
snoRNA prec 22,776 6,544 2,774 32,094 0% 0% 0% 71% 20% 9%
plasmid 9,461 3,193 1,896 14,550 0% 0% 0% 65% 22% 13%
scaRNA 10,065 2,184 526 12,775 0% 0% 0% 79% 17% 4%
snRNA prec 7,207 2,076 1,934 11,217 0% 0% 0% 64% 19% 17%
piRNA 1,227 866 1,283 3,376 0% 0% 0% 36% 26% 38%
scRNA prec 173 43 132 348 0% 0% 0% 50% 12% 38%
adapter 0 0 160 160 0% 0% 0% 0% 0% 100%
doubtful miRNA 101 42 14 157 0% 0% 0% 64% 27% 9%
mirtron 24 5 1 30 0% 0% 0% 80% 17% 3%
scaRNA prec 10 8 1 19 0% 0% 0% 53% 42% 5%
std cali 0 0 1 1 0% 0% 0% 0% 0% 100%
total 88,636,592 19,751,610 5,978,938 114,367,140 93% 100% 100% n/a n/a n/a
2.2 Bioinformatics analysis pipeline
2.2.1 Hierarchical sequence read mapping
In parallel with the tRNA annotation procedure, I had to build a bioinformatics
pipeline for processing the obtained sequence information. To account for the
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multiple maturation steps between pre- and mature tRNAs, in collaboration with
bioinformatician Miguel Brown, we developed an iterative, hierarchical approach
for mapping and annotating our sequence reads.
First we mapped reads to reference tRNA genes for the human genome re-
lease hg19 (http://gtrnadb.ucsc.edu/) using an iterative and hierarchical pro-
tocol (Fig. 2.1B). We started by mapping only to mature tRNAs, which included
the 3’ CCA aminoacyl acceptor terminus, and the G-1 nucleotide added posttran-
scriptionally to histidine tRNAs [40, 48], but excluded tRNA introns. Starting with
two most abundant tRNA transcripts per tRNA isotype, as indicated after the first
mapping round, except for selenocysteine, where only one mature tRNA sequence
could be identified, we performed iterative rounds of mapping and manual refer-
ence transcript selection, focusing in every step on transcripts that collected more
reads with an error distance of 1 or 2 than reads without errors. If these reads with
mismatches could be assigned to other tRNA isoacceptors, these were included
in our candidate reference set. Otherwise, we reasoned that the mismatches
were the results of nucleotide-modification-induced errors of RT. In those cases,
we accounted for the modified nucleoside signatures by introducing a new, edited
reference transcript in our set.
For tRNAs that exhibited multiple positions with high modification rates (>10%
compared to reference), we compiled reference sequences with all possible com-
binations of modified signatures at all detectably modified positions, aiming to ac-
count for the maximum possible number of mapped sequence reads. We ended
the curation cycles when there was no observed modified position that exhibited a
mismatch frequency greater than or equal to 10% compared to the reference. By
performing this iterative process of curation, we obtained an experimentally vali-
dated reference set of mature tRNAs accounting for modified-nucleotide-induced
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sequence variation upon reverse transcription.
2.2.2 tRNA gene annotation
In order to identify possible tRNA gene loci, we mapped the curated tRNA se-
quences back to the genome, allowing for gaps to accommodate tRNA introns,
as well as up to 7 mismatches to accommodate terminal and internal RNA edit-
ing events. By appending 40 nts upstream and downstream of the location of
genomic mapping, we obtained a candidate pre-tRNA gene set. We mapped non-
annotated residual reads to these candidates to identify 5’ leader- and 3’ trailer-
comprising pre-tRNA reads. These reads distinguished actively transcribed tRNA
genes from silent ones or pseudogenes.
Leader- and trailer-comprising tRNA genes show higher sequence variation,
as evidence by higher information entropy values, across the leader and trailer
nucleotides than internal sequences within the mature tRNA suggesting that even
short precursor sequences with read coverage are sufficient for the annotation of
non-redundant tRNA genes (Fig. 2.2). At the end of our analysis we accounted
for 93% of the 114,367,140 reads in our deepest library (Table 2.1).
Given the depth of sequencing, we are confident that we accounted for the
vast majority of precursor and mature tRNAs. Indeed, a posteriori we looked
for genomic regions that collected at least 50 overlapping reads throughout their
whole length, fell within the 60- to 100-nt size window, and adopted a cloverleaf
structure, in an effort to detect any tRNAs that might have been overlooked by
our approach or in prior literature. The only sequences that we identified were U1
snRNA (pseudo)genes, suggesting that our analysis was exhaustive, at least for
tRNAs in HEK293 cells.
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Figure 2.2: Information entropy in pre-tRNA segments and mature body.
(A,B) Information entropy H = −
∑n
i=1 p(i) ∗ log(p(i)), (where p is the frequency of
each nucleotide at a given position, i, and n the total number of transcripts) was
calculated using from hydro-tRNAseq for the 5’ leader and 3’ trailers of all pre-
tRNAs with positions centered at the 5’ and 3’ ends of mature tRNAs. Pre-tRNA
fragments are shorter than 15 nt; hence the drop in signal. (C,D) Same as before,
but using the reference sequence of mature tRNAs.
2.3 Pipeline outputs
2.3.1 Mature tRNA alignment
Our pipeline provides individual alignments for every reference transcript included
in our curated database. Each alignment is presented in a separate text file (.txt)
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that can be surveyed without the requirement of any special analysis or display
software, as is the case for conventional mRNA-seq packages.
Figure 2.3: Mature tRNA alignment. An indicative alignment to mature TRNAE5
is shown, including read sequences and counts, mapping locations, and log4 bin-
normalized abundance.
Figure 2.3 shows a representative alignment of reads to a mature glutamate-
tRNA reference (TRNAE5). The name of the transcript is shown at the top, and
the reference transcript sequence at the bottom of the file. Pile-ups of of reads
that were mapped to the reference are sorted in descending order of abundance,
shown in the ’count’ column. Due to the intentional fragmentation of input RNA,
we observe that the majority of reads were shorter than the full length tRNA. Thus,
longer reads (like the one boxed at the lower part of the alignment) are used to
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bridge together separate segments. The total mapping locations for multimapping
reads are also indicated. Vertical lines represent the relative frequency of binned,
normalized read count in log4 increments. The 3’ CCA aminoacyl acceptor ter-
minus is shown in red indicating the hydro-tRNAseq is successful in freeing the
terminus from charged amino acids.
2.3.2 Pre-tRNA alignment
As part of the hierarchical mapping protocol, reads that are not accounted for
during the generation of mature tRNA alignments are mapped to our curated pre-
tRNA reference sequences, which span 40 nt up- and downstream from all mature
tRNA boundaries. Figure 2.4 shows a representative alignment of reads to a glu-
tamate pre-tRNA reference (TRNAE26), similar to Fig. 2.3. The mature sequence
is shown in blue, while the leader and trailer sequences in green.
Figure 2.4: Pre-tRNA alignment. An indicative alignment to pre-tRNA TRNAE5
is shown. Mature sequence is in blue and precursor-specific sequence segments
in green. The anticodon is boxed in blue for orientation purposes.
The simplicity of the output files of our pipeline renders them easily exploitable
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for downstream bioinformatics analysis, necessitating only intermediate program-
ming skills. At the same time the alignment displays can be used directly in figure
making. As a matter of fact, simple, and easily customizable Perl and Python
scripts were used for all the analysis presented in section 3, showcasing the ease
of primary sequence data access and analysis conferred by our approach.
2.4 Need for pre-tRNA enrichment
The majority of our reads obtained from 60-100 nt size-fractionated total RNA were
assigned to mature tRNAs. The improvement we observed in recovering tRNA
reads was considerable, as 2/3 of our reads mapped to either mature (nuclear
or mitochondrial) or pre-tRNAs. Nevertheless, only 1% of total reads comprised
sequences overlapping with pre-tRNA leader or trailer sequences (Fig. 2.5, Table
2.1). This raised the possibility that we might have missed reads corresponding
to lowly expressed or very rapidly processed pre-tRNAs. We controlled for this by
Figure 2.5: Composition of hydro-tRNAseq libraries. Total RNA composition
of the 60-100 nt size fraction from hydro-tRNAseq according to RNA classes.
performing photoactivatable-ribonucleoside-enhanced crosslinking and immuno-
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precipitation (PAR-CLIP) and sequencing, a technique developed in our lab to
identify RNA targets of RNA-binding proteins (RBPs) with high specificity [49].
2.5 PAR-CLIP methodology for the study or RNA-
RBP interactions
A series of techniques have been developed for the study of RNA-RBP interac-
tions on a genomic scale [50]. Our lab developed PAR-CLIP, coupled with deep
sequencing, which is a cell-based approach that allows the determination of RBP
binding sites on RNA targets at nucleotide-level resolution (Fig. 2.6). To enable
efficient RNA-RBP crosslinking using long wavelength UV light, 4-thiouridine (4-
SU) is added to culture medium, taken up by cells and incorporated into nascent
transcripts. The crosslinked ribonucleoprotein complex is submitted to partial
RNase digestion, immunopurification and size-fractionated. Crosslinked RNA is
recovered, converted into small RNA cDNA libraries, and sequenced. Importantly,
crosslinking introduces a structural change in the thiouridine base, which allows
pinpointing the position of crosslinking by scoring for characteristic T-to-C transi-
tions in the sequenced cDNA. In addition, the abundant background derived from
non-crosslinked fragments of co-purifying cellular RNAs do not contain these T-
to-C transitions and can be filtered out. Thus, PAR-CLIP has a very low rate of
false positive target identification, since the nucleotide transition signature reliably
marks true crosslinking sites. PAR-CLIP has so far been applied successfully to




Figure 2.6: PAR-CLIP. Experimental outline of PAR-CLIP methodology, as de-
scribed previously [49].
2.6 SSB PAR-CLIP
In collaboration with Aitor Garzia, we decided to complement our sequencing ef-
forts with PAR-CLIP-sequencing of the protein Sjögren syndrome type B antigen
(SSB), which is also known as Lupus La protein (La) (Fig. 2.7). SSB has been
shown biochemically to bind to the short 3’ oligoU tails [51] that acts as termina-
tion signal for POLR3 [52]. Therefore, we reasoned that SSB should bind all tRNA
precursors, and that if we could isolate its targets, we would be able to reliably
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Figure 2.7: SSB crosslinking to RNA. Phosphorimage of SSB-crosslinked to
radiolabeled RNA. PAR-CLIP was performed using RNase A or RNase T1, at
two different concentrations to account for possible biases of RNase treatment
conditions. Libraries from PAR-CLIP using 1 U/µL of RNase A and RNase T1
were prepared and submitted for sequencing. Western blot against HA, shown in
the bottom, confirmed the immunoprecipitation of SSB.
identify transcribed tRNA loci.
SSB exhibited a striking binding preference for pre-tRNAs and showed a dras-
tic enrichment in precursor tRNAs compared to hydro-tRNAseq (Fig. 2.8), which
confirmed our hypothesis, as well as previous observations [53]. We performed
PAR-CLIP using two different nucleases to control for sequence biases at the nu-
clease digestion step. RNase T1 resulted in longer precursor tRNA trailer se-
quences than RNase A, due the latter’s preference for cleaving 3’ to pyrimidines,
which are highly abundant in the 3’ trailer sequences. Overall, 46% of all PAR-
CLIP reads mapped to pre-tRNAs (Fig. 2.8A), the overwhelming majority of which
showed the characteristic T-to-C transition, indicative of crosslinking (Fig. 2.8B,
Table 2.2).
The vast majority of crosslinking sites in pre-tRNAs were concentrated, as ex-
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Type D0 counts D1 counts D2 counts Total Percent of total
pre-tRNA 8,249,237 45,310,051 18,719,097 72,278,385 46%
tRNA 8,687,821 16,903,928 7,278,511 32,870,260 21%
rRNA 3,120,687 15,480,966 2,745,431 21,347,084 14%
mRNA gene 1,446,452 4,200,866 10,423,676 16,070,994 10%
mRNA 396,184 2,788,499 7,499,514 10,684,197 7%
scRNA 243,364 1,543,873 305,333 2,092,570 1%
lincRNA gene 81,146 224,548 335,874 641,568 0%
adapter 282,626 90,077 8,183 380,886 0%
snRNA 37,462 131,211 31,302 199,975 0%
snoRNA 11,203 54,179 16,072 81,454 0%
miRNA 3,228 17,382 20,827 41,437 0%
scRNA prec 5,979 23,546 7,876 37,401 0%
piRNA 8,573 1,671 9,102 19,346 0%
plasmid 5,344 4,722 6,301 16,367 0%
mt rRNA 11,006 2,866 979 14,851 0%
mt tRNA 3,356 5,942 2,617 11,915 0%
snoRNA prec 703 5,030 2,362 8,095 0%
rRNA prec 2,076 3,549 1,548 7,173 0%
mt mRNA 1,017 1,783 3,207 6,007 0%
scaRNA 198 2,654 1,708 4,560 0%
marker 1,739 208 27 1,974 0%
lincRNA 698 515 714 1,927 0%
long cali 3 151 662 816 0%
doubtful miRNA 176 140 203 519 0%
snRNA prec 13 66 37 116 0%
scaRNA prec 6 37 7 50 0%
mirtron 2 17 6 25 0%
circRNA 0 0 14 14 0%
std cali 0 1 10 11 0%
Ome cali 0 2 5 7 0%
alt cali 0 0 3 3 0%
doubtful snoRNA 1 0 1 2 0%
pected, in the oligoU tract of the 3’ trailer sequence (Fig. 2.9). We also found
that SSB crosslinked to the 5’ segment of the mature tRNA body at conserved
sites in the D-stemloop (Fig. 2.9B), which is a novel finding, hinted at by a report
proposing that the affinity of SSB for a full-length pre-tRNA cannot be explained
solely by its binding to the 3’ oligoU tract [53]. The other major target of SSB was
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Table 2.2: SSB PAR-CLIP reads per RNA type. Reads assigned to each RNA 
type following hierarchical annotation are shown. Reads with no (d0), one (d1) or 
two (d2) mismatches compared to reference are shown. Data from replicate using 
RNase T1 are shown. SSB PAR-CLIP enriches for pre-tRNAs (46%).
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Figure 2.8: SSB binds pre-tRNAs. (A) Assignment of reads from SSB PAR-CLIP
(RNase T1, 1 U/µL) to RNA types. (B) SSB PAR-CLIP reads mapping to tRNA
precursors with 0, 1 or 2 mismatches (d0, d1, d2); reads with T-to-C mismatches
are separated (red) from the rest of the reads with one mismatch (gray). Read
length and number of reads are represented on the x- and y-axis, respectively.
5S ribosomal RNA (rRNA), which is the only POLR3-transcribed rRNA, and, as
such, also terminates with an oligoU stretch to which SSB crosslinked (Fig. 2.10).
2.7 tRNA gene annotation
I combined hydro-tRNAseq and SSB PAR-CLIP to identify actively transcribed
tRNA genes (genomic locations that give rise to a supported pre-tRNAs). I could
confidently identify 288 tRNA genes as the intersection of 4 replicates of hydro-
tRNAseq (Fig. 2.11A), and 349 tRNA genes as the intersection of two SSB PAR-
CLIP experiments (Fig. 2.11B). Of note, SSB PAR-CLIP confirmed the expression
of an additional 7 tRNA genes that were not supported in hydro-tRNAseq replicate
(Fig. 2.11C), further showcasing the complementarity of the two approaches.
There was a strong correlation of pre-tRNA abundances between SSB PAR-CLIP
and hydro-tRNAseq (Pearson R = 0.72; Fig. 2.11D), providing confidence that
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Figure 2.9: SSB binds the 3’ oligoU stretch of pre-tRNAs. (A) Positional pref-
erence of SSB crosslinking by metagene analysis of all crosslinking events to
precursor tRNAs. The incidence of T-to-C transitions is indicated by color inten-
sity. (B) Positional preference of SSB crosslinking by metagene analysis of reads
mapped hierarchically; first to mature and then to precursor tRNAs. For each
class, PAR-CLIP signal (reads containing T-to-C) and background (reads with no
mismatches) are shown. The normalized boundaries of pre-tRNAs (labeled as
0,1) and mature tRNAs (labeled as 5’ end, 3’ end), and read count are shown on
the x- and y-axis, respectively.
SSB PAR-CLIP quantitatively detected pre-tRNAs, without introducing biases (e.g.
artificially enriching for lowly expressed pre-tRNAs). The correlation of identified
isoacceptor counts between SSB PAR-CLIP and hydro-tRNAseq was virtually per-
fect (Pearson R = 0.99; Fig. 2.12A), ruling out the introduction of a pronounced
systematic bias from our hydrolysis-based protocol. Some anticodons seemed to
be served by multiple tRNA isodecoders (e.g. 19 isodecoders for tRNASerGCA),
while others only from one (e.g. tRNASerACT;Fig. 2.12B).Selenocysteine was the
only amino acid that, in our data, was decoded by only one tRNA gene.
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Figure 2.10: SSB binds 5S rRNA. (A) Assignment of reads from SSB PAR-
CLIP to rRNAs. (B) Abundance of reads mapped to 5S rRNA with 0, 1 or 2 mis-
matches (d0, d1, d2) as a function of read length; reads with T-to-C mismatches
are separated (red) from the rest of the reads with one mismatch (gray). Read
length and number of reads are represented on the x- and y-axis, respectively.
(C) Read alignments corresponding to 5S rRNA. Crosslinked positions are shown
in red. The read count is shown next to each read sequence, followed by the to-
tal mapping positions, and the mapping positions that contain a T-to-C transition.
Crosslinked and non-crosslinked read coverage is graphically represented.
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Figure 2.11: tRNA gene annotation. (A) Venn diagram of expressed tRNA genes
detected by hydro-tRNAseq in HEK293 cells. Genes with read evidence in both
the 5’ leader and 3’ trailer of the pre-tRNA were counted. (B) Bar chart showing
the number of pre-tRNAs detected in each replicate of hydro-tRNAseq and SSB
PAR-CLIP. (C) Example of one out of seven tRNA genes that were detected by
SSB PAR-CLIP, but were not detected in any of four hydro-tRNAseq replicates.
(D) Correlation of relative read frequencies (log2-transformed) of precursor tRNAs
between hydro-tRNAseq (x-axis) and SSB PAR-CLIP (y-axis). Correlation was
calculated using the Pearson test. Linear fit is shown in red. The y=x line (dotted)
is shown for comparison.
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Figure 2.12: Number and relative abundance of tRNA genes per isotype and
isoacceptor. (A) Correlation of gene counts for each anticodon detected by hydro-
tRNAseq (y-axis) and SSB PAR-CLIP (x-axis). Each dot represents an anticodon
shown in (B). Correlation was calculated using the Pearson test. (B) Number of
tRNA genes for each anticodon and isotype. Hydro-tRNAseq data are shown in
black (mean of 4 replicates; error bars represent standard deviation), SSB PAR-
CLIP (RNase T1 treated) in red. (C) Correlation of relative read frequency (y-axis)
of mature tRNAs with number of genes (x-axis) per tRNA isotype. Hydro-tRNAseq
data; four replicates; mean values shown; error bars represent standard deviation.
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Applications and biological insights
3.1 tRNA gene abundance does not correlate with
tRNA gene count on the isotype level
Having established the rigor and validity of our experimental and computational
method, I set out to address long-standing questions related to tRNA biology.
First, I asked whether there is a linear relationship between number of tRNA genes
(which will from now on be used interchangeably with pre-tRNAs) and the collec-
tive abundance of tRNAs for a given isotype. Due to the absence of reliable tR-
NAseq datasets, it was assumed that tRNA abundance increased monotonically
with increasing tRNA gene count [12, 19, 20].
This proposition hinged on the assumption that tRNAs undergo insignificant
transcriptional or post-transcriptional gene regulation, and thus all tRNA genes are
transcribed and contribute equally to the mature tRNA abundance. It dismissed,
thus, any possible mechanisms of affecting steady state tRNA levels, such as
modulation of transcription, processing and degradation.
Indeed, recent data, albeit scant and based on array-type experiments, sug-
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gested that the tRNA repertoire can be regulated in a dynamic fashion, and might
not even be associated with tumor biology [21]. My analysis lent credence to the
concept of tRNA regulation. I showed that although tRNA isotypes with higher rel-
ative abundances generally tend to have higher tRNA gene numbers, there is no
linear correlation between read frequency and gene count (R = 0.12; Fig. 2.12C).
3.2 tRNA gene abundance does not correlate with
tRNA gene count on the isoacceptor level
The same non-monotonic relationship seems to be true also on the level of tRNA
isoacceptors. The relevant data are presented in Fig. 3.1. The complexity of
the collective data presentation merits a detailed explanation (please note that a
reader-friendlier version of the figure is shown in Appendix 12.6). In detail the
figure shows:
• tRNA isotypes as headers, using single-letter amino acid codes
• anticodons (representing tRNA isodecoders) on the x-axis
• tRNA gene count (average of four hydro-tRNAseq replicates) on the y-axis
• relative mature tRNA read frequency per anticodon, normalized over all tR-
NAs (proportional to the area of each disc)
Even though, for example, cysteine-tRNAGCA is the tRNA with the highest gene
count, glycine-tRNAGCC is the tRNA with the highest abundance. Also, proline
tRNAs are a telling counterexample, whereby the AGG isodecoders are encoded
by the largest number of genes, but represent the least abundant set. At the same
time, it becomes evident that the tRNA repertoire in HEK293 cells can decode 47
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out of the 62 coding codons (61 canonical and one for selenocysteine,TGA) by
Watson-Crick basepairing, being thus, dependent on wobble basepairing for the
remaining set.
Figure 3.1: Average gene count and relative frequency for each anticodon.
The gene count (mean of 4 replicates) is shown on the y-axis, anticodons on the
x-axis; isotypes are indicated on the top. The area of each black disc is propor-
tional to the fraction of reads mapping to all mature tRNAs for a given anticodon,
normalized over all mature tRNAs for all anticodons.
3.3 Mature tRNA abundance does not correlate with
pre-tRNA abundance
The next question that arose, was whether there is a correlation between individ-
ual pre-tRNAs and their mature transcripts. If that were the case, then one could
conclude that tRNA maturation is a uniform process across all tRNAs that occurs
without significant regulation on individual tRNAs.
Neither of the two techniques I employed showed any strong correlation be-
tween precursor and mature tRNA counts (R < 0.2; 3.2A,B). Our techniques can
reproducibly quantify pre-tRNAs (Fig. 2.11D), and detect accumulation of pre-
tRNA processing intermediates (see section 3.7). Therefore, the observed lack
of correlation is likely due to marked differences in the kinetics and dynamics of
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processing across tRNAs, and/or their pre-tRNA fragments’ degradation, rather
than due to experimental limitations in capturing processing intermediates.
Figure 3.2: Correlation between pre-tRNA and mature tRNA read frequen-
cies. Correlation of relative read frequencies (log2-transformed) between pre-
tRNA (x-axis) and mature tRNAs (y-axis) for SSB PAR-CLIP (A) and hydro-
tRNAseq (B). Correlation was calculated using the Pearson test. Linear fit is
shown in red. The y=x line (dotted) is shown for comparison. (C) Representa-
tive alignments of a mature tRNA (top) and its corresponding precursor (bottom).
On the pre-tRNA reference, the mature sequence is labeled in blue, and the leader
and trailer sequences in green, with their borders demarcated by vertical dotted
lines. The post-transcriptionally added CCA tail is shown in red on the mature ref-
erence sequence. Vertical bars represent binned, log4-transformed abundance.
With respect to individual tRNAs, however, mature tRNA read counts were
always higher than the respective pre-tRNA counts (Fig. 3.2C). This suggests
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that tRNA processing is an efficient process across the tRNA spectrum, leading to
prompt removal of intermediates and preventing accumulation of fragments that
could possibly be toxic to the cells [44].
3.4 tRNA transcription initiation and termination
Besides tRNA gene annotation and quantification, I realized that my approach
could yield insights into POLR3 transcription initiation and termination, by pay-
ing attention to the length and characteristics of pre-tRNA leader and trailer se-
quences. To the best of my knowledge, such an analysis had not been previously
performed on a transcriptome-wide level in human cells, even though elegant work
had yielded valubale insights either in vitro or in silico, predominantly in yeast [52,
54–58].
Figure 3.3: Boundaries of tRNA transcription initiation and termination. His-
togram of the length distribution of precursor tRNA 5’ leaders (A) and 3’ trailers (B)
detected by hydro-tRNAseq, and trailers detected by SSB PAR-CLIP (C). Mean ±
standard deviation of four hydro-tRNAseq replicates shown in (A) and (B). Data
from SSB PAR-CLIP replicate with RNase T1 shown in (C).
Based on hydro-tRNAseq, I determined the median 5’ leader and 3’ trailer
lengths to be 6 and 10 nt, respectively, with the trailer lengths showing a broader
distribution, centered around 12 nt (Fig. 3.3A,B). Interestingly, SSB PAR-CLIP
revealed a subset of much longer trailers (Fig. 3.3C), suggesting that it captured
34
Chapter 3 3.5
the very initial steps of precursor tRNA processing, and accordingly that hydro-
tRNAseq captures pre-tRNAs partially trimmed, either by ELAC2 (tRNase Z) or
some other nuclease [34].
I next focused on the POLR3 oligoU termination signals. Various reports in
the past have focused on the oligoU requirements for transcription termination in
different species [55, 57]. SSB protected consistently a 4 to 5 nt oligoU stretch,
which was also confirmed by hydro-tRNAseq (Fig. 3.4). This is in agreement with
previous in vitro results [51, 53, 59]. I also addressed the proposed requirement
for a stem-loop immediately upstream of the oligoU termination signal [55]. Sec-
ondary structure predictions for the trailer sequences with documented sequence
evidence in hydro-tRNAseq and SSB PAR-CLIP did not detect predicted stable
stem-loop structures for approximately half of all pre-tRNAs (Fig. 3.5). This ar-
gued against a formal requirement for a stem-loop in the termination process of
POLR3, at least on tRNA genes, in accordance with previous biochemical evi-
dence [57].
Figure 3.4: POLR3 oligoU transcription termination signals. Histogram of the
length distribution for the longest oligoU tract per pre-tRNA 3’ trailer detected by
hydro-tRNAseq (A) (aggregate gene total of all replicates shown on the y-axis),
and by SSB PAR-CLIP (B).
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Figure 3.5: Predicted structures of precursor tRNA 3’ trailers with read evi-
dence in SSB PAR-CLIP. Every colored box indicates one nucleotide. Red and
blue reflect the 5’ and 3’ parts of a duplex, respectively, whereas gray indicates
non-basepaired nucleotides. About 1/2 of all tRNA trailers lack any predicted
structure (right panel). The predicted stemloops do not have a uniform stem or
loop length. Folding was performed using the Vienna folding package [60].
3.5 Ribonucleotide modifications
RT across modified nucleotide-containing RNA leads to errors in cognate de-
oxynucleotide incorporation, revealed by mismatches in sequence reads upon
mapping to reference genomic sequence. Read coverage across regions with a
high degree of modifications may result in incomplete or largely uneven coverage.
Therefore, the compilation of my tRNA reference set, included the combination of
all frequent mismatch signatures in all heavily modified positions. I reported the
most frequently modified positions per tRNA gene (Table 3.1), and computed the
frequencies of every nucleoside change per position across all tRNA genes (the
most common ones shown in Fig. 3.6).
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Table 3.1: Positions resulting to
modifications-induced mismatches.
tRNA transcripts, the positions where
modifications result in mismatches, and
the read count corresponding to every
observed nucleoside per position are
shown.
tRNA Position Nucleoside Read count
trnaA10 36 G 25,957
trnaA10 36 T 1,198
trnaA10 36 A 2,206
trnaA10 36 C 51
trnaA11 36 A 100
trnaA11 36 T 61
trnaA11 36 G 95
trnaA13 6 C 2,507
trnaA13 6 T 175,171
trnaA13 6 A 1,178
trnaA13 6 G 6,873
trnaA13 10 G 185,402
trnaA13 10 T 39
trnaA13 10 A 829
trnaA13 10 C 136
trnaA13 16 C 1,134
trnaA13 16 T 189,165
trnaA13 16 G 1,038
trnaA13 33 C 112
trnaA13 33 A 386
trnaA13 33 T 110
trnaA13 33 G 205,885
trnaA13 36 C 559
trnaA13 36 T 12,584
trnaA13 36 A 4,747
trnaA13 36 G 173,085
trnaA13 39 A 30
trnaA13 39 T 3,993
trnaA13 39 C 172,312
trnaA13 45 T 319
trnaA13 45 C 1,202
trnaA13 45 G 65,025
trnaA13 56 G 126
trnaA13 56 T 7
trnaA13 56 A 36,136
trnaA13 56 C 40
trnaA13 58 A 13
trnaA13 58 T 36,111
trnaA13 58 C 117
trnaA13 58 G 6
trnaA13 66 T 62
trnaA13 66 A 32,876
trnaA13 66 C 684
trnaA2 34 G 33,023
trnaA2 34 A 206
trnaA2 34 T 11
trnaA2 34 C 9
trnaA2 37 A 1,135
trnaA2 37 T 9,316
trnaA2 37 C 250
trnaA2 37 G 23,009
trnaA23 5 G 12,936
trnaA23 5 C 593
Continued on next column
Continued from previous column
tRNA Position Nucleoside Read count
trnaA23 5 T 250
trnaA23 5 A 277,684
trnaA23 33 C 206,326
trnaA23 33 T 215,944
trnaA23 33 A 126
trnaA23 36 A 9,456
trnaA23 36 T 18,956
trnaA23 36 G 415,552
trnaA23 46 G 992
trnaA23 46 A 366
trnaA23 46 T 102,084
trnaA23 46 C 145,919
trnaA23 67 C 2,990
trnaA23 67 T 145,047
trnaA23 67 A 16
trnaA28 33 A 98
trnaA28 33 T 50
trnaA28 33 C 1,180
trnaA28 33 G 38,349
trnaA28 36 G 26,060
trnaA28 36 C 54
trnaA28 36 A 922
trnaA28 36 T 1,098
trnaA28 45 T 478
trnaA28 45 A 19
trnaA28 45 C 21
trnaA28 45 G 7,579
trnaA3 34 C 25
trnaA3 34 A 205
trnaA3 34 T 26
trnaA3 34 G 101,158
trnaA3 37 G 79,503
trnaA3 37 C 673
trnaA3 37 T 28,670
trnaA3 37 A 2,886
trnaA32 36 C 155
trnaA32 36 A 107,454
trnaA32 36 T 254
trnaA32 36 G 7,740
trnaA32 45 G 74,872
trnaA32 45 C 3,688
trnaA32 45 A 75
trnaA32 45 T 1,610
trnaA34 33 G 33,690
trnaA34 33 C 15
trnaA34 33 A 219
trnaA34 33 T 20
trnaA34 36 G 27,770
trnaA34 36 T 2,594
trnaA34 36 A 1,468
trnaA34 36 C 128
trnaA6 33 G 2,435
trnaA6 33 C 7
trnaA6 33 T 6
trnaA6 33 A 5,790
trnaA6 36 G 3,318
trnaA6 36 C 31
trnaA6 36 A 4,344
trnaA6 36 T 380
trnaA7 33 A 1,183
trnaA7 33 T 1,892
trnaA7 33 C 1,117
trnaA7 33 G 27,108
trnaA7 36 G 20,964
trnaA7 36 T 12,246
trnaA7 36 A 3,841
Continued on next column
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Continued from previous column
tRNA Position Nucleoside Read count
trnaA7 36 C 594
trnaC10 6 G 15,648
trnaC10 6 C 101,951
trnaC10 6 T 2,423
trnaC10 6 A 5,244
trnaC10 16 G 26,551
trnaC10 16 C 2,047
trnaC10 16 A 1,356
trnaC10 16 T 117,667
trnaC11 16 C 10
trnaC11 16 T 783
trnaC11 16 G 4,230
trnaC11 44 A 82
trnaC11 44 T 10
trnaC11 44 G 803
trnaC14 6 G 4,417
trnaC14 6 C 2,002
trnaC14 6 A 762
trnaC14 6 T 92,027
trnaC14 57 A 47,747
trnaC14 57 T 5,006
trnaC14 57 C 391
trnaC14 57 G 6,331
trnaC21 42 G 33,541
trnaC21 42 C 73
trnaC21 42 A 7,594
trnaC21 42 T 181
trnaC24 6 G 5,664
trnaC24 6 T 95,339
trnaC24 6 A 1,284
trnaC24 6 C 16,078
trnaC24 57 T 9,354
trnaC24 57 A 139,890
trnaC24 57 C 339
trnaC24 57 G 9,511
trnaC7 57 G 1,048
trnaC7 57 T 931
trnaC7 57 A 25,533
trnaC7 57 C 20
trnaD10 9 G 813
trnaD10 9 T 304
trnaD10 9 A 118,147
trnaD10 9 C 89
trnaD10 53 C 19,831
trnaD10 53 A 1,716
trnaD10 53 T 472,250
trnaD10 53 G 45,707
trnaD10 56 G 367,491
trnaD10 56 C 1,093
trnaD10 56 T 846
trnaD10 56 A 144,309
trnaD10 57 G 2,914
trnaD10 57 T 16,380
trnaD10 57 A 492,772
trnaD10 57 C 791
trnaD9 24 C 468
trnaD9 24 A 4,669
trnaD9 24 T 1,114
trnaD9 24 G 2,101
trnaD9 31 C 91,720
trnaD9 31 T 2,596
trnaD9 31 A 953
trnaD9 31 G 2,238
trnaD9 56 A 114,699
trnaD9 56 T 609
trnaD9 56 C 858
Continued on next column
Continued from previous column
tRNA Position Nucleoside Read count
trnaD9 56 G 1,051,388
trnaD9 57 G 9,918
trnaD9 57 A 1,095,714
trnaD9 57 T 59,596
trnaD9 57 C 2,145
trnaE5 9 G 913,314
trnaE5 9 A 1,503
trnaE5 9 T 1,502
trnaE5 9 C 1,330
trnaE5 19 G 668
trnaE5 19 A 198
trnaE5 19 T 1,171,172
trnaE5 19 C 3,141
trnaE5 24 G 18,086
trnaE5 24 A 1,368,739
trnaE5 24 T 2,320
trnaE5 24 C 2,252
trnaE5 27 G 4,750
trnaE5 27 T 27,560
trnaE5 27 A 3,180
trnaE5 27 C 1,490,638
trnaE5 34 C 1,948,790
trnaE5 34 A 1,036
trnaE5 34 T 45,989
trnaE5 34 G 1,246
trnaE5 53 G 46,498
trnaE5 53 A 3,717
trnaE5 53 T 1,971,842
trnaE5 53 C 16,977
trnaE5 57 G 27,513
trnaE5 57 C 12,646
trnaE5 57 A 1,784,527
trnaE5 57 T 163,808
trnaE7 6 G 442
trnaE7 6 T 224,221
trnaE7 6 A 428
trnaE7 6 C 622,013
trnaE7 9 G 925,734
trnaE7 9 A 1,682
trnaE7 9 T 3,498
trnaE7 9 C 1,570
trnaE7 34 G 7,239
trnaE7 34 C 63,597
trnaE7 34 T 1,701,031
trnaE7 34 A 5,025
trnaE7 44 A 3,111
trnaE7 44 T 209,800
trnaE7 44 C 1,445,839
trnaE7 44 G 8,730
trnaE7 66 C 36
trnaE7 66 T 1,122
trnaE7 66 A 154,605
trnaE7 66 G 1,018,843
trnaF5 6 A 1,703
trnaF5 6 C 36
trnaF5 6 G 1,587
trnaF5 47 G 783
trnaF5 47 T 17,158
trnaF5 47 C 2,431
trnaF5 57 A 3,199
trnaF5 57 G 16,069
trnaG15 5 G 983,413
trnaG15 5 T 477,119
trnaG15 5 A 2,009
trnaG15 5 C 5,058
trnaG15 45 G 1,455,904
Continued on next column
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Continued from previous column
tRNA Position Nucleoside Read count
trnaG15 45 T 3,715
trnaG15 45 A 131,627
trnaG15 45 C 10,529
trnaG15 56 C 2,347
trnaG15 56 T 137,083
trnaG15 56 A 802,531
trnaG15 56 G 23,277
trnaG15 66 G 13
trnaG15 66 A 556,240
trnaG15 66 C 353,038
trnaH11 5 A 687
trnaH11 5 T 1,239
trnaH11 5 C 243
trnaH11 5 G 9,794
trnaH11 33 A 729
trnaH11 33 T 897,345
trnaH11 33 C 5,452
trnaH11 33 G 8,216
trnaH11 58 G 20,143
trnaH11 58 C 260
trnaH11 58 T 27,065
trnaH11 58 A 870,683
trnaI5 27 G 2,177
trnaI5 27 T 1,830
trnaI5 35 G 32,621
trnaI5 35 A 107
trnaI5 60 A 3,085
trnaI5 60 T 36,960
trnaI5 69 G 36,009
trnaI5 69 T 2,962
trnaI9 27 T 2,220
trnaI9 27 A 90
trnaI9 27 C 79
trnaI9 27 G 18,350
trnaI9 35 G 54,591
trnaI9 35 T 7
trnaI9 35 A 189
trnaI9 59 G 1,438
trnaI9 59 C 229
trnaI9 59 T 3,282
trnaI9 59 A 43,060
trnaI9 60 G 9
trnaI9 60 C 27
trnaI9 60 A 3,213
trnaI9 60 T 44,664
trnaI9 69 T 5,705
trnaI9 69 C 92
trnaI9 69 G 38,915
trnaK1 54 G 12,329
trnaK1 54 T 529,905
trnaK1 54 A 2,946
trnaK1 54 C 7,353
trnaK1 58 C 1,742
trnaK1 58 T 22,380
trnaK1 58 A 435,401
trnaK1 58 G 81,542
trnaL1 27 G 52,413
trnaL1 27 T 4,682
trnaL1 27 A 2,091
trnaL1 27 C 717
trnaL1 35 C 21
trnaL1 35 T 2,285
trnaL1 35 A 546
trnaL1 35 G 68,859
trnaL1 67 G 1,793
trnaL1 67 C 221
Continued on next column
Continued from previous column
tRNA Position Nucleoside Read count
trnaL1 67 A 55,644
trnaL1 67 T 2,456
trnaL15 10 G 12,159
trnaL15 10 T 13
trnaL15 10 A 12
trnaL15 10 C 863
trnaL15 12 G 5
trnaL15 12 T 647
trnaL15 12 A 2
trnaL15 12 C 12,503
trnaL15 27 C 80
trnaL15 27 A 316
trnaL15 27 T 720
trnaL15 27 G 12,945
trnaL4 27 G 21,789
trnaL4 27 T 812
trnaL4 35 G 21,913
trnaL4 35 A 202
trnaL4 67 T 206
trnaL4 67 A 3,302
trnaL4 67 G 176
trnaL5 51 G 4,824
trnaL5 51 C 24,212
trnaL5 51 T 19,749
trnaL5 51 A 2,548
trnaM1 9 G 85,934
trnaM1 9 C 6,935
trnaM1 9 A 5,666
trnaM1 9 T 23,834
trnaM1 57 A 312,240
trnaM1 57 T 18,020
trnaM1 57 C 1,202
trnaM1 57 G 12,797
trnaM13 20 G 779
trnaM13 20 T 20,233
trnaM13 20 A 393
trnaM13 20 C 2,235
trnaM13 26 A 802
trnaM13 26 T 3,204
trnaM13 26 C 113
trnaM13 26 G 34,706
trnaM13 58 G 6,039
trnaM13 58 A 372,150
trnaM13 58 T 7,682
trnaM13 58 C 894
trnaM13 59 G 141,279
trnaM13 59 C 1,112
trnaM13 59 T 243,802
trnaM13 59 A 273
trnaN1 27 C 5,696
trnaN1 27 A 5,664
trnaN1 27 T 133,510
trnaN1 27 G 250,204
trnaN1 59 T 79,049
trnaN1 59 A 827,307
trnaN1 59 C 4,741
trnaN1 59 G 127,829
trnaN14 27 G 102,061
trnaN14 27 A 4,021
trnaN14 27 T 21,768
trnaN14 27 C 1,392
trnaN14 59 G 7,434
trnaN14 59 C 706
trnaN14 59 A 151,684
trnaN14 59 T 9,968
trnaP10 19 C 4,621
Continued on next column
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Continued from previous column
tRNA Position Nucleoside Read count
trnaP10 19 A 2,631
trnaP10 19 T 411,265
trnaP10 19 G 45,430
trnaP10 33 C 183,783
trnaP10 33 T 89,056
trnaP10 33 A 1,332
trnaP10 33 G 461,368
trnaP10 39 G 3,517
trnaP10 39 T 81,988
trnaP10 39 A 972
trnaP10 39 C 592,210
trnaQ1 56 C 1,480
trnaQ1 56 A 1,768,755
trnaQ1 56 T 617
trnaQ1 56 G 8,734
trnaQ1 57 G 29,151
trnaQ1 57 T 4,802
trnaQ1 57 A 1,692,736
trnaQ1 57 C 2,268
trnaQ1 58 G 23,220
trnaQ1 58 T 1,535
trnaQ1 58 A 1,685,855
trnaQ1 58 C 7,182
trnaQ2 32 A 147
trnaQ2 32 T 391
trnaQ2 32 C 220,622
trnaQ2 32 G 38,543
trnaR10 19 G 880
trnaR10 19 C 25
trnaR10 19 T 77
trnaR10 19 A 66,484
trnaR10 34 T 42
trnaR10 34 A 4,136
trnaR10 34 C 51
trnaR10 34 G 115,152
trnaR10 58 G 4,908
trnaR10 58 A 68,405
trnaR10 58 T 2,439
trnaR10 58 C 227
trnaR2 19 G 6,415
trnaR2 19 T 133
trnaR2 19 A 122,886
trnaR2 19 C 97
trnaR2 34 G 238,519
trnaR2 34 C 203
trnaR2 34 A 6,830
trnaR2 34 T 160
trnaR2 58 G 11,883
trnaR2 58 A 152,011
trnaR2 58 T 4,470
trnaR2 58 C 653
trnaR22 58 C 1,653
trnaR22 58 T 28,134
trnaR22 58 A 325,452
trnaR22 58 G 53,856
trnaR25 32 C 164,623
trnaR25 32 T 25,406
trnaR25 32 A 171
trnaR25 32 G 161
trnaR25 34 G 78
trnaR25 34 C 41,819
trnaR25 34 T 187,213
trnaR25 34 A 115
trnaR25 58 C 1,903
trnaR25 58 A 242,429
trnaR25 58 T 29,879
Continued on next column
Continued from previous column
tRNA Position Nucleoside Read count
trnaR25 58 G 51,224
trnaR4 37 C 2,958
trnaR4 37 T 10,499
trnaR4 37 A 2,141
trnaR4 37 G 384,444
trnaR4 58 G 54,001
trnaR4 58 A 392,684
trnaR4 58 T 30,994
trnaR4 58 C 1,602
trnaR7 58 A 150,051
trnaR7 58 T 5,083
trnaR7 58 C 537
trnaR7 58 G 3,895
trnaS16 52 C 6,033
trnaS16 52 A 2,966
trnaS16 52 G 5,330
trnaT14 35 G 87,515
trnaT14 35 C 513
trnaT14 35 T 326
trnaT14 35 A 159
trnaT14 59 G 3,635
trnaT14 59 T 10,441
trnaT14 59 A 108,722
trnaT14 59 C 746
trnaT2 26 C 209
trnaT2 26 A 16,122
trnaT2 26 T 20
trnaT2 26 G 61
trnaT2 58 G 39
trnaT2 58 T 833
trnaT2 58 A 5,715
trnaT2 58 C 18
trnaT21 35 A 19
trnaT21 35 T 490
trnaT21 35 C 48
trnaT21 35 G 9,748
trnaT21 59 A 10,638
trnaT21 59 T 240
trnaT21 59 C 59
trnaT21 59 G 1,403
trnaT4 35 C 538
trnaT4 35 T 2,319
trnaT4 35 A 472
trnaT4 35 G 210,546
trnaT4 59 G 18,477
trnaT4 59 C 1,524
trnaT4 59 T 21,160
trnaT4 59 A 325,542
trnaT4 70 G 3,512
trnaT4 70 C 4,114
trnaT4 70 A 1,371
trnaT4 70 T 345,239
trnaU1 28 C 39
trnaU1 28 A 15
trnaU1 28 T 3,002
trnaU1 28 G 97
trnaU1 64 A 61
trnaU1 64 T 7,513
trnaU1 64 C 112
trnaU1 64 G 385
trnaU1 71 T 706
trnaU1 71 A 6,359
trnaU1 71 C 10
trnaU1 71 G 67
trnaV12 34 G 10,863
trnaV12 34 C 11,001
Continued on next column
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Continued from previous column
tRNA Position Nucleoside Read count
trnaV12 34 A 122
trnaV12 34 T 221
trnaV12 67 G 59,792
trnaV12 67 A 1,838
trnaV12 67 T 344
trnaV12 67 C 376
trnaV2 19 G 4,257
trnaV2 19 C 10,750
trnaV2 19 A 1,121
trnaV2 19 T 889,930
trnaV2 20 G 202
trnaV2 20 C 361,327
trnaV2 20 T 546,333
trnaV2 20 A 678
trnaV2 26 G 873,859
trnaV2 26 A 5,271
trnaV2 26 T 46,502
trnaV2 26 C 7,245
trnaV2 34 C 445,948
trnaV2 34 A 1,387
trnaV2 34 T 2,668
trnaV2 34 G 948,953
trnaV2 58 G 67,711
trnaV2 58 A 946,402
trnaV2 58 T 101,713
trnaV2 58 C 5,446
trnaV27 26 G 416,151
trnaV27 26 C 3,461
trnaV27 26 T 18,759
trnaV27 26 A 1,627
trnaV27 58 G 13,799
trnaV27 58 C 1,270
trnaV27 58 T 21,819
trnaV27 58 A 168,700
trnaV8 34 A 471
trnaV8 34 T 525
trnaV8 34 C 47,407
trnaV8 34 G 84,016
trnaW2 70 C 708
trnaW2 70 A 165
trnaW2 70 T 12,759
trnaW2 70 G 1,040
trnaW5 70 G 2,127
trnaW5 70 C 1,492
trnaW5 70 T 71,434
trnaW5 70 A 320
trnaW7 57 G 2,443
trnaW7 57 C 49
trnaW7 57 A 65,298
trnaW7 57 T 331
trnaW7 70 C 1,174
trnaW7 70 T 58,462
trnaW7 70 A 291
trnaW7 70 G 2,288
trnaY12 26 G 1,265
trnaY12 26 T 131
trnaY2 26 G 1,003
trnaY2 26 T 85
trnaY2 26 C 11
trnaY2 37 G 10,310
trnaY2 37 C 365
trnaY2 37 A 37
trnaY2 37 T 461
trnaY4 26 G 8,449
trnaY4 26 A 102
trnaY4 26 T 380
Continued on next column
Continued from previous column
tRNA Position Nucleoside Read count
trnaY4 26 C 41
trnaY4 37 T 540
trnaY4 37 A 8
trnaY4 37 C 1,197
trnaY4 37 G 22,102
trnaY4 58 G 3,462
trnaY4 58 A 26,513
trnaY4 58 T 14,753
trnaY4 58 C 190
trnaY4 59 C 98
trnaY4 59 A 9,871
trnaY4 59 T 34,855
trnaY4 59 G 81
trnaY8 26 G 1,450
trnaY8 26 C 32
trnaY8 26 A 45
trnaY8 26 T 122
trnaY8 51 G 5
trnaY8 51 A 14
trnaY8 51 T 17,882
trnaY8 51 C 2,101
trnaY8 58 G 610
trnaY8 58 A 17,992
trnaY8 58 T 1,254
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The majority of editing events were A-to-G transitions at the first position of
the anticodon (position 34) and at the position 3’ to the anticodon (position 37).
Both positions are known to be heavily modified, the former being deaminated to
inosine, and the latter further modified (e.g. 1-methylinosine) [61]. In my data
the majority of the reads that mapped to the anticodon of the modified tRNAs
contained mismatches. To a lesser extent I could also detect 1-methyladenosine
in the pseudouridine loop (returned as A-to-T or A-to-G), and various guanosine
modifications at positions 9, 26, and 45, which most likely correspond to 1-methyl-,
N2,N2-dimethyl-, and 7-methyl-guanosine, respectively [61].
Figure 3.6: tRNA modifications detected by hydro-tRNAseq. The positions
that resulted in the most common mismatches over all tRNAs, along with the refer-
ence nucleotide and the most likely modification are indicated in the center of each
ring. The relative frequency of each returned nucleoside is proportional to the cor-
responding color-coded area of the ring (m1G: 1-methylguanosine; m2,2G: N2,N2-
dimethylguanosine; I: inosine; m1I: 1-methylinosine; m7G: 7-methylguanosine;
m1A: 1-methyladenosine).
The temporal resolution of tRNA modifications by RNAseq has begun to be ad-
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dressed recently [62], however at a single modification level (inosine 34), and by
using libraries relative poor in tRNA reads (<1% of total reads). I was appropriately
poised to address this issue since my very deep sequencing set, in combination
with my hierarchical annotation pipeline, offered the advantage of dissecting mul-
tiple modifications simultaneously.
I focused on inosine editing events, since they represented the majority of mod-
ified nucleosides. By inspecting read alignments with error distance 1 to the ref-
erence pre-tRNA, I noticed A-to-G transition mismatches at position 34 in reads
that retained the leader and trailer sequences of the precursor tRNA (Fig. 3.7,
top). This confirmed that A34 deamination takes place at the precursor level, and
therefore is a nuclear modification, as it has been previously reported [62].
Next, I noticed that 1-methyl-inosine at position 37 also appears at the precur-
sor stage. Of note the A37 modification became apparent prior to A34, as the
majority of the error distance 1 reads contained a mismatch at A37. Reads with
two mismatches contained both modifications (Fig. 3.7, bottom).
All in all, far from being a comprehensive analysis of tRNA editing and mod-
ifications, the work presented here outlines how a careful examination and anal-
ysis of deep hydro-tRNAseq datasets can yield valuable insights in the and type
and temporal occurrence of such events. Such analysis is paramount to avoiding
misassignment of sequencing reads when dealing with highly similar reference
sequences.
3.6 Annotation of intron-containing tRNA genes
Intron-containing tRNAs represent a particularly interesting set of tRNA genes,
as mutations in their evolutionarily conserved, yet distinct, processing machinery
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Figure 3.7: Temporal resolution of tRNA modifications. Read alignments for
precursor TRNAA6 with one (top) and two mismatches (bottom). The position
of the anticodon is marked by the black rectangle at the top of the alignments.
Mismatches of the heavily modified adenosines in the anticodon loop are indicated
by red lowercase letters. Read counts and mapping locations for each read are
shown on the right side. Vertical bars represent binned, log4-transformed, and
normalized read counts for each alignment.
have emerged recently as causes of severe neurodevelopmental syndromes, such
as pontocerebellar hypoplasia [4, 45, 63]. Therefore, there is documented need
for a comprehensive annotation of human intron-containing tRNAs, which should




Figure 3.8: Intron-containing pre-tRNA alignment. An indicative alignment to
pre-tRNA TRNAY15 is shown. Mature sequence is in blue, leaders and trailers
in green, and intron sequences in orange. Precursor/mature tRNA borders are
demarcated by vertical, dotted lines.
I set out to document all intron-containg tRNAs. Read coverage across both
exon/intron boundaries in the pre-tRNA alignments was a requirement for the val-
idation of intron-containing tRNAs (e.g. Fig. 3.8). I confirmed 26 out of 32 pre-
dicted intron-containing tRNAs by hydro-tRNAseq (Fig. 3.9A). Intriguingly, I could
not confirm expression of any predicted intronless tyrosine pre-tRNA gene. The
same was true for isoleucine-TAT and leucine-CAA isoacceptors.Excluding any
unknown biologically redundant mechanism, this suggests that the integrity of the




Figure 3.9: Annotation of intron-containing tRNA genes. (A) Number of val-
idated intron-containing (orange) and intronless (blue) tRNA genes for all tRNA
isotypes with possible intron-containing tRNAs. (B), (C) Analysis of PAR-CLIP
for the tRNA ligase, RTCB (previously published in [64]). Positional preference of
crosslinking by metagene analysis of all crosslinking events (B) and all crosslinked
reads (C) to mature tRNAs. The incidence of T-to-C transitions is indicated by color
intensity in (B). PAR-CLIP signal (reads containing T-to-C), background (reads with
no mismatches), normalized boundaries of the pre-tRNAs (labeled as 0, 1) and
mature tRNAs (labeled as 5’ end, 3’ end) are shown in (C).
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To further confirm my observations, I coupled hydro-tRNAseq results with pre-
viously published PAR-CLIP data on the human tRNA ligase, RTCB [64]. Despite
the shallow read depth of the dataset, I identified a crosslinking peak (RBP bind-
ing site) at the anticodon loop of all intron-containing tRNAs annotated by my
approach (Fig. 3.9B,C.
3.7 Hydro-tRNAseq application in human disease
These observations came at an opportune moment because of novel contribu-
tions of tRNA processing ongoing efforts to characterize the human disease in-
volvement of cleavage and polyadenylation factor I subunit 1 (CLP1), a 5’ RNA
kinase involved in tRNA splicing [31]. Before my studies, it was shown that mouse
models with CLP1 that lacked its catalytic activity develop severe neuromuscular
defects accentuated by loss of motor neurons and muscular paralysis [44].
Human exome capture and sequencing from individuals with ponotcerebellar
hypoplasia identified a homozygous missense mutation in CLP1 (chr11:g.57,427,367
G > A [hg19], p.R140H) in five unrelated, but consanguineous families, resulting
in an autosomal recessive pattern of inheritance (Fig. 3.10). Biochemical studies
showed that this autosomal mutation reduces the interaction affinity of CLP1 for
the splicing complex [46].
However, it was not clear whether this had any molecular effect on tRNA pro-
cessing. I applied hydro-tRNAseq on RNA isolated from parental and patient fi-
broblasts. Initially, there was no significant difference in the steady-state levels of
either mature (for example Fig. 3.11, right part) or pre-tRNAs as reported by our
bioinformatics pipeline.
Interestingly, however, manual inspection of all pre-tRNA alignments revealed
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Figure 3.10: Pedigrees of families with CLP1-induced syndromes. Pedigrees
of three nuclear families with patients showing microcephaly, pontocerebellar hy-
poplasia, dysmorphic facial features and severe neuromuscular abnormalities.
CLP1 p.R140H follows autosomal recessive inheritance. Double lines indicate
consanguineous marriages; squares and circles represent male and female sub-
jects, respectively. Black-filled shapes indicate patients.
a reproducible accumulation of intronic sequences for specific pre-tRNAs (Fig.
3.11, left part) in patient samples. The same pattern was observed in two more
pre-tRNAs, all of which showed >4-fold accumlation of intronic sequences (Fig.
3.12).
These results were confirmed independently by our collaborators (Stefan Weitzer,
Javier Martinez, IMBA Vienna) who carried out northern blot analysis on the same
RNA samples. Consistent with my results, they failed to detect significant differ-
ences in steady-state mature or pre-tRNA levels between parents and patients
(Fig. 3.13, top-most pannels), but detected an accumulation of the salient tRNA
introns of my analysis (Fig. 3.13, middle panels). Densitometric analysis of the
northern blots also confirmed the trend and range of intron accumulation across




Figure 3.11: Hydro-tRNAseq analysis of CLP1 patient fibroblasts. Example
of an isoleucine pre-tRNA (left part) and mature tRNA (right part) alignment for
a matched parent (top) - patient (bottom) pair. Accumulating intronic reads are
bracketed. The exon/exon junction is indicated in the mature tRNA alignments.
Figure 3.12: CLP1 mutation leads to intronic read accumulation. Quantifica-
tion of intronic reads for three different pre-tRNAs for parents (black and grey bars)
and patients (red and orange bars). Hydro-tRNAseq data shown on the left, and
northern blot data on the right.
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Figure 3.13: Northern blot analyses of RNA from parental and patient fibrob-
lasts. A probe complementary to the 5’ exon of isoleucine-TAT and tyrosine-GTA
tRNAs was used to detect mature and pre-tRNA species (top panels). Probes
specifically directed against intron sequences were used to detect pre-tRNAs and
tRNA introns of two isoleucine-TAT and one tyrosine-GTA tRNA (middle panels).
U6 snRNA served as loading control (bottom panels). Asterisks denote truncated
pre-tRNA species.
3.7.1 Plausible pathomechanisms of CLP1 mutations
Thus, northern analysis and deep sequencing data indicate that the CLP1 R140H
mutation in fibroblasts influences processing of pre-tRNAs, resulting in the accu-
mulation of tRNA introns, whereas pre- and mature tRNA levels remain largely
unaffected. Nevertheless, at this point the biological mechanisms responsible for
the pathogenicity of CLP1 mutations are not clear.
During intron removal, cleavage by tRNA splicing and endonuclease complex
(TSEN) leaves a 3’ cyclic phosphate on the 5’ tRNA exon and a 5’ OH on the 3’
exon (Fig. 3.14). These moieties are substrates of the tRNA ligase (RTCB), which
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Figure 3.14: Model of CLP1 involvement in tRNA splicing. CLP1 associates
with the TSEN complex, which endonucleolytically removes tRNA introns (labeled
in blue). The cleavage results in a 3’ cyclic phosphate and 5’ OH on the 5’ and
3’ exons, respectively, which are ligated by RTCB (canonical ligation). CLP1 can
also phosphorylate the 3’ exon which could then be ligated to the 5’ half by an
unknown ligase. CLP1 could also phosphorylate the removed intron facilitating its
removal by an exonuclease.
carries out the ligation of the two tRNA halves. CLP1 is capable of phosphorylating
the 5’ end of the 3’ exon, possibly allowing the ligation of the two halves by a yet
unknown ligase [31], which would be reminiscent of the tRNA splicing pathway in
yeast [45].
Alternatively, CLP1 could be phosphorylating the excised intron, which harbors
a 5’ OH immediately after cleavage. The "healing" of the 5’ end of the linear intron
is a requirement for its degradation, at least in yeast, by the 5’-3’ exonuclease
Xrn1 [65]. Altogether, taking into account both the documented and hypothesized
functions of CLP1, one could come up with the following testable hypotheses re-
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garding the plausible pathomechanisms of CLP1 mutations:
• tRNA splicing and mature tRNA levels are reduced in metabolically sensitive
tissues (e.g. neurons), while they are unaffected in fibroblasts.
• tRNA intron accumulation leads to innate immunity activation.
• tRNA splicing proteins have pleiotropic, and possibly tRNA-unrelated effects
(e.g. participation in mRNA polyadenylation [30, 45])
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Comparison with other methods
Recently tRNA sequencing methods have been developed that employ dealky-
lating enzymes and/or highly thermostable reverse transcriptase to overcome re-
spectively the hurdles of modifications and stable structures that impede tRNA
sequencing [27, 28]. However, they both have specific limitations that I tried to
address. I size-selected at a higher size window to avoid contamination by tRNA-
derived fragments (as compared to [27]). Also, I used two sequential adapter
ligation methods to make sure that only full-length fragments were sequenced
and the sequencing reads were not results of blocks during RT (as compared to
[28]), which allowed me to differentiate RT stops from fragment ends. Additionally,
I did not bias our sequencing protocol towards mature tRNAs, but instead cap-
tured more precursors by both hydro-tRNAseq and more importantly PAR-CLIP
methods, which enabled a deeper pre-tRNA curation. Importantly, despite the re-
portedly high processivity conferred by dealkylating methyl modifications, in the
previous studies only a small fraction of reads mapped at a given transcript were
full-length reads (<1% of all reads), with a marginal increase compared to un-
treated controls (Fig. 4.1).
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Figure 4.1: Read length distribution for hydro-tRNAseq and dealkylating se-
quencing methods. The fraction of reads with a given length is indicated for
hydro-tRNAseq, as well as untreated and treated samples from dealkylating meth-
ods. The distribution of tRNA lengths is shown in dotted blue lines on the right
y-axis for comparison.
In contrast, hydro-tRNAseq yielded a higher cumulative fraction of mature tR-
NAs with read evidence across their whole length with a mean read coverage of
0.99 of the full length (compared to 0.95 and 0.87 in previous studies; Fig. 4.2).
Also, SSB PAR-CLIP was more sensitive in identifying tRNA genes, detecting 349
genes as compared to ∼ 159 and ∼ 212 in the other methods.
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Figure 4.2: Mature tRNA read coverage by hydro-tRNAseq and dealkylating
sequencing methods. Histogram representing the fraction of normalized mature
tRNA transcript length with ungapped and overlapping read evidence in hydro-
tRNAseq and tRNA sequencing methods employing dealkylation steps (control




I have combined two complementary transcriptome-wide approaches to provide
experimentally validated annotation for mature and pre-tRNA transcripts and their
respective genes, in addition to furnishing an accurate quantification of tRNA
abundance in human cells.
First, I developed hydro-tRNAseq, a fragmentation-based protocol for over-
coming hurdles of tRNA sequencing, and obtained deep sequencing sets that
enabled the annotation of tRNA genes and derivation of mature tRNA reference
sequences for accurately assigning sequence reads to the otherwise edited and
nucleotide-modified original tRNA pool. Alkaline hydrolysis of the tRNA-containing
pool relieved thermodynamically stable structural constraints that impair ligation
steps in the cDNA library preparations, reduced the number of modified nucleo-
sides per sequenced fragment, resulting in high read-through in the RT step, and
release of the 3’ hydroxyl group of the otherwise aminoacylated tRNA 3’ end.
Then, I took advantage of the pre-tRNA binding properties of SSB protein,
which coordinates posttranscriptional processing and maturation of tRNAs [52], to
enrich for tRNA precursors and allow for a comprehensive curation of pre-tRNA
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transcripts and annotation of tRNA genes. Of note, since SSB interacts with pre-
tRNAs and other small nuclear RNA’s U-rich 3’ ends in all organisms examined
so far [59, 66], this approach can be adapted towards tRNA annotation in other
species.
My data suggest that, at least in my experimental system, the tRNA gene
space is considerably more contracted than it has been previously predicted by
bioinformatics, evidenced by the fact that almost half of the predicted tRNA loci
were transcriptionally silent, presumably representing retrointegrated tRNA pseu-
dogenes or epigenetically silenced regions. It would be interesting to examine
whether such an observation holds for various cell types and at different stages of
development or disease, in order to confirm the differential expression and regu-
lation of tRNA gene expression that has been reported before [21, 26].
Furthermore, my approach allowed the elucidation of relevant issues regard-
ing POLR3 transcription such as the length of pre-tRNA leaders and trailers,
the length of oligoU required for recognition by SSB, both of which have shown
species specificity [58]. I detected that 4 sequential Us act as the transcription
termination signal for POLR3, confirming similar predictions based on genomic
sequences that suggested a requirement for 4 Us for efficient termination in ver-
tebrates [56, 67], as well as structural data documenting the capacity of SSB to
accommodate 4 Us in its binding site [51, 59]. At the same time, the length dis-
tribution of the oligoU tract identified in our experiments reflects the heterogeneity
of termination signal lengths that has been noted as an intrinsic property of poly-
merase III in vitro [58].
I could also confirm a second binding site of SSB in the 5’ half of the mature
tRNA sequence, in support of previous observations proposing the presence of
additional pre-tRNA binding sites besides the 3’ tail [51, 53]. It has been previously
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noted that the binding mode of SSB to tRNA is more complex than the recognition
alone of the 3’ tails, and that one of the RNA recognition motifs present in SSB,
RRM1, could bind elsewhere in the tRNA. This stems from two observations:
i) SSB has a higher affinity for precursor over mature tRNAs,
ii) structural data show that RRM1 is unoccupied when SSB is bound to UUU-
3’-OH substrate.
My data seem to validate this observation, and could shed light into new modes of
SSB-mediated processing of pre-tRNAs into either mature tRNAs or other kinds
of ncRNAs [14].
Moreover, I was able to carry out a careful overview and tRNA modifications
that result in characteristic mismatch signatures. I introduced all possible combi-
nations of all “mutated” nucleotides at the most prominently modified positions in
every tRNA in order to collect as many reads that could be having RT misincor-
porations at the modified positions. This created a large number of similar tRNA
sequences, and therefore I allowed for extensive multimapping, but split the read
counts in order to avoid artificial read count inflation. By making use of our hier-
archical annotation pipeline, I was able to dissect the temporal order of inosine
modifications at the tRNA anticodon, confirming that A34 deamination occurs in
the nucleus prior to the nucleolytic processing of the pre-tRNA, and establishing
that the same holds true for A37 modifications, which in fact precede A34 deami-
nation.
Accounting for modification signatures was also important for the reason that
CLIP-seq, and especially PAR-CLIP, depends on apparent mismatches (in the
case of PAR-CLIP, T-to-C conversions) for the identification of RBP binding sites
on target RNAs. Since I used PAR-CLIP of SSB for the annotation of pre-tRNAs
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and tRNA genes, I first examined uridine modifications that result in T-to-C con-
versions. Only a small minority of modification signatures were T-to-C transitions,
suggesting that it is highly unlikely that our PAR-CLIP data were artificially inflated.
Then, I applied my protocols towards the elucidation of mechanisms of human
disease, in a multi-collaborative effort to characterize a novel, severe neurode-
velopmental syndrome caused by mutations in the tRNA kinase CLP1 [46]. By
applying the hydro-tRNAseq protocol and analysis pipeline, I identified the accu-
mulation of intronic sequences in the patient samples, a finding which was con-
firmed independently by northern blot analysis. This constituted a demonstrative
proof-of-principle that tailored-RNAseq protocols can be of considerable value in
the context of diagnostics.
5.1 Summary
In summary I have shown that:
i) hydro-tRNAseq is a facile and efficient method for sequencing tRNAs
ii) PAR-CLIP of SSB/La informs the annotation tRNA genes and curation of pre-
tRNAs
iii) combined together, the two techniques can help answer long-standing ques-
tions of tRNA biogenesis, processing and function






Total RNA from HEK293 (Flp-In T-REx, Invitrogen) was isolated using TRIzol
(Invitrogen). For each sample 20 µg of total RNA were resolved on 12% urea-
polyacrylamide gels and recovered within a size window of 60-100 nt. The eluted
fraction was subjected to limited alkaline hydrolysis in a 15 µL buffer of 10 mM
Na2CO3 and 10 mM NaHCO3 at pH 9.7 either at 65 °C for 10 min (replicate 1) or
1 h (replicates 2-4).
The partially hydrolyzed RNA was dephosphorylated with 10 U of calf intestinal
phosphatase (NEB) in a 50 µL reaction of 100 mM NaCl, 50 mM Tris-HCl, pH 7.9
at 25 °C, 10 mM MgCl2, 1 mM DTT, 3 mM Na2CO3 and 3 mM NaHCO3, at 37 °C
for 1 h. The resulting RNA was re-phosphorylated with 10 U of T4 polynucleotide
kinase (NEB) in a 20 µL reaction of 70 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 5
mM DTT and 1 mM ATP, at 37 °C for 1 h. Fragments of 19-35 nt were con-
verted into barcoded small RNA cDNA libraries, as previously described [47], and




view/200/458. Sequencing read alignments were performed using the Burrows-
Wheeler aligner against an in-house curated and annotated list of mature and
precursor tRNAs containing predicted tRNA sequences for human genome ver-
sion hg19
http://gtrnadb.ucsc.edu. Sequencing reads were first mapped against mature
tRNAs. Remaining reads were mapped against genomic tRNA sequences that
included 5’ leader and 3’ trailer sequences, as well as tRNA introns.
6.2 SSB PAR-CLIP
Flp-In T-REx HEK293 cells (Invitrogen) were grown in high glucose DMEM sup-
plemented with 10% (v/v) FBS, 1 mM sodium pyruvate, 100 U/mL penicillin, 100
µg/mL streptomycin, 100 µg/mL zeocin and 15 µg/mL blasticidin. Cell lines sta-
bly expressing FLAG/HA- (FH-) SSB were generated as described previously
[68]. Expression of FH-SSB was induced by addition of 1 µg /mL doxycycline
for 24 h. 4-SU PAR-CLIP was performed as described previously, using either
RNase T1 or RNase A [69]. PAR-CLIP cDNA libraries were sequenced on an Il-
lumina HiSeq 2500 instrument. Adapter extracted reads were aligned against an
in-house curated and annotated list of mature and precursor mRNAs and ncR-
NAs. Bioinformatic analysis was performed using a analysis pipeline based on
a curated and annotated reference RNA collection, which we organized into cat-
egories, such as rRNA, tRNA, snoRNA, mRNAs, etc. This pipeline is available
at https://rnaworld.rockefeller.edu/PARCLIP_suite/. T-to-C conversion fre-




Reads were mapped to our transcriptomic database with error distance 0 (d0),
1 (d1) or 2 (d2), allowing mismatches, insertions and deletions. Assignment of
reads with more than one mapping locations that belong to different RNA classes
followed a hierarchical procedure reflective of the cellular abundance of each RNA
class. Mature RNA sequences (e.g. fully processed tRNAs) received priority com-
pared to precursors (e.g. pre-tRNAs), thus minimizing multimapping events. A
tRNA gene was considered to be expressed when there were reads spanning the
precursor/mature junctions, including exon/intron junctions for intron-containing
tRNAs. For abundance reports, multimapping reads were split equally over the
number of their mapping locations, and all reads mapping to edited and non-edited
versions of the same tRNA transcript were summed for quantification of a given
tRNA. Naming of tRNAs followed HUGO guidelines, with edited variants of refer-
ence tRNAs exhibiting the edited position and the identity of induced mismatch
in their naming. The same analysis pipeline was applied to mitochondrial tRNAs,
with the exception that no tRNA precursors were annotated due to continuous
transcription of the mitochondrial genome. Remaining reads that did not map to
any annotated transcript were mapped to the human genome. The mapped read
annotation process was based on a hierarchical procedure that assigned prior-
ity to reads mapping in their entirety to mature sequences, followed by reads that
spanned the precursor-mature junctions. Bioinformatic analysis was performed by




The RNAseq and PAR-CLIP sequence data have been deposited in the National
Center for Biotechnology Information (NCBI) Sequence Read Archive under ac-
cession numbers GSE95683.
6.5 Code availability
All scripts used for the analysis (written in Perl, Python and R) are available upon
request, and will also be deposited on https://github.com/tgogakos upon pub-







Even though tRNA biology has been studied extensively in the past, there are still
fundamental parts in the lifecycle of tRNAs that remain unexplored in humans.
For example, the 3’ end processing of human tRNAs is not completely understood
[52]. On one hand, this can be attributed to divergent evolutionary trajectories of
tRNA processing pathways within Eukarya, resulting, for example in great differ-
ences in tRNA splicing and nucleocytoplasmic dynamics (this has already been
alluded to here in section 3.7.1), but has been surveyed in much greater detail
and eloquence elsewhere [34, 35, 70]). On the other hand, tRNA processing and
expression is characterized by multiple levels of evolutionary and functional redun-
dancy (e.g. multiple translation factors, editing enzymes, multicopy genes). One
could speculate, and explain the emergence of such redundant mechanisms in
light of the essentiality of tRNA biogenesis for life.
Given the incomplete knowledge of human tRNA processing proteins, I was
interested in studying such potentially novel factors. Thus, I turned my attention to
component 3 promoter of RISC (C3PO), which is a conserved, multisubunit com-
plex of the RBP translin (TSN) and translin-associated protein X, also known as
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TRAX (TSNAX) [71]. This complex has been associated with various biological
functions, ranging from double stranded DNA (dsDNA) damage response, RNA
interference (RNAi) enhancement, and has also been involved neurologic devel-
opment [71–75].
Both members of the complex contain a previously undescribed RNA recogni-
tion motif, and TSNAX possesses RNA endonucleolytic activity both in vitro and
in vivo, with a preference for single stranded RNA (ssRNA) [76, 77]. The crystal
structure of the C3PO complex, with or without substrates, from various organisms
has also been reported, and has determined a tight octameric assembly, con-
sisting of six TSN and two TSNAX monomers [76–78]. Its biological importance
is underscored by the neurodegenerative phenotypes observed in mice lacking
components of the complex [74].
Interestingly, it was recently observed that loss of C3PO in the fungus N. crassa
and in mouse fibroblasts results in accumulation of tRNA fragments (tRFs), ele-
vated levels of mature tRNAs, enhanced protein translation, and increased re-
sistance to cell death-inducing agents [79]. This unexpected finding suggested
that C3PO might be a novel tRNA processing enzyme, at least in the two stud-
ied species. Despite these studies, though, the biological targets and the details
of the biochemical activity of C3PO remain elusive. Moreover, it is not yet clear
whether C3PO is important for the biogenesis of tRNAs, the generation of compe-





I carried out PAR-CLIP in order to identify the transcriptome-wide targets of C3PO.
I used inducible cell lines expressing a FLAG-HA-TSN or FLAG-HA-TSN-(2A)-
TSNAX*-HA construct, under the control of a doxycycline-inducible promoter.
TSNAX* had two mutations in the endonuclease active site, because induction of
a catalytically active TSNAX proved lethal in our system (data not shown). Both
ORFs were cloned in tandem, with an intervening self-cleaving 2A intein peptide,
in order to control their concomitant expression and their relative stoichiometry as
tightly as possible.
PAR-CLIP on C3PO confirmed its role as a bona fide tRNA binding protein,
since tRNAs collected the largest fraction of sequenced reads (Fig. 8.1A), with the
characteristic T-to-C signature (Fig. 8.1B). Of note, my PAR-CLIP results seem
to bring into question previous reports that implicated C3PO in enhancing RNAi
activity by promoting miRNA-mediated gene silencing, since only 0.2% of the total
reads mapped to miRNAs. However, a large percentage of binding sites (referred
to as clusters) was in 5’ UTRs (∼22% of total), a result that came as a surprise,
as C3PO has not been reported to interact with 5’ UTRs before.
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Figure 8.1: C3PO crosslinks to tRNAs. (A) Pie chart, showing distribution of
C3PO PAR-CLIP reads. (B) C3PO PAR-CLIP reads mapping to mature tRNA with
0, 1 or 2 mismatches (d0, d1, d2); reads with T-to-C mismatches are separated
(red) from the rest of the reads with one mismatch (gray). Read length and number
of reads are represented on the x- and y-axis, respectively.
Metagene analysis of the tRNA clusters and crosslinking sites showed that
C3PO interacts with the dihydro-uridine stemloop (D stemloop) (Fig. 8.2), and it
shows preference for Us located adjacent to the conserved di-G sequence in the
loop (nt 16-19 in Fig. 8.3).
Since the detected binding site on tRNAs is conserved both in sequence and
in structure, it was not clear whether the di-G motif was necessary for binding
or whether C3PO was just recognizing the stemloop structure. Motif enrichment
analysis showed that the same or a highly similar motif always containing the di-G
sequence was present in non-tRNA targets of C3PO (Fig. 8.4), which would sug-




Figure 8.2: Metagene analysis of C3PO crosslinking to mature tRNAs.
(A) Positional preference of C3PO crosslinking by metagene analysis of reads
mapped hierarchically; first to mature and then to precursor tRNAs. PAR-CLIP
signal (reads containing T-to-C) from two replicates is shown (C3PO and TSN).
The normalized boundaries of pre-tRNAs (labeled as 0,1) and mature tRNAs (la-
beled as 5’ end, 3’ end), and T-to-C counts are shown on the x- and y-axis, re-
spectively. (B) Positional preference of C3PO crosslinking by metagene analysis
of all crosslinking events to mature tRNAs. The incidence of T-to-C transitions is
indicated by color intensity.
Figure 8.3: Weblogo of 5’ tRNA sequences. Information entropy across the
5’ half of all tRNAs shows high nucleotide conservation at various positions, and
especially at the C3PO binding site(nt 16-19. Weblogo was created using http:
//weblogo.berkeley.edu/logo.cgi. See also Fig. 2.2.
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Figure 8.4: Motif analysis of C3PO RNA targets. Predicted RNA recogni-
tion motifs shown for total clusters, as well as the most common types of clus-
ters grouped by RNA category. 5’ UTR clusters are shown separately from
total mRNA clusters, due to their high enrichment. Number of corresponding





9.1 C3PO possesses a length- and structure-
dependent endonucleolytic activity
It was previously observed in our lab that the endonucleolytic activity of C3PO
is much reduced for RNA substrates longer than 80 nt (unpublished data). This
cutoff is very close to the average length of a mature human tRNA (75 nt). The
length cut-off of C3PO’s activity along with the presence of tRNAs in its PAR-CLIP
target list prompted the in vitro study of C3PO’s nuclease activity on tRNAs.
I performed cleavage assays on 5’ or 3’ labeled, in vitro transcribed histidine
(tRNAHis, 76 nt) and serine-tRNA (tRNASer, 85 nt) (Fig. 9.1). These substrates
were chosen because of their confirmed presence in the PAR-CLIP dataset, and
because they lie inside and outside the length-dependent window of optimum nu-
clease activity, respectively. My data suggested that tRNAHis is a favored sub-
strate, consistent with the length preference of C3PO. More importantly, I noticed
that C3PO elicits a structure-dependent cleavage pattern with respect to tRNAs.
C3PO activity does not lead to processive degradation of the tRNA substrates
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Figure 9.1: C3PO in vitro cleavage assay. Recombinant C3PO and 5’ in vitro
transcribed and radiolabeled tRNAs, identified as PAR-CLIP targets were used in
cleavage assays (left panel). RNase T1 and hydrolysis were used as reference to
map cleavage sites. The sequences used are shown in the bottom, and the major
cleavage sites for tRNAHis are labeled on the figure. The secondary structure of
the same tRNA is shown on the right, with C3PO binding site labeled in yellow ,
and crosslinked residues in red.
(see hydrolysis ladder [H] in Fig. 9.1), but rather results in products of specific
length (≤ 9 nts). This suggests that C3PO cleaves preferentially at the shoulders
of the acceptor stem of tRNAs.
9.1.1 EMSAs
In order understand the requirements for interactions of C3PO with its substrates,
I performed electrophoretic mobility shift assays (EMSAs) with either TSN or cat-
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alytically inactive C3PO, and a wide range of substrates, including G-homo-oligomers,
single stranded GGU repeats and short RNA stemloops containing C3PO’s puta-
tive binding motif (Fig. 9.2).
Figure 9.2: EMSA analysis of TSN and C3PO. Recombinant TSN or C3PO (with
mutated catalytic site) was incubated with chemically synthesized, 5’ radiolabeled
oligonucleotides. Stemloop substrates are shown below the respective panels.
G11, G13: oligo-G substrates; (GGU)6: 18-nt-long oligo of GGU tandem repeats.
The results showed the following:
• both TSN and C3PO bind to PAR-CLIP identified stemloops
• C3PO shows a stepwise binding pattern, indicated by the formation of an
intermediate product
• C3PO prefers GGU repeats over G-homo-oligomers, which suggests direct
contribution of U residues to binding
• C3PO binds stemloops better than linear or dsRNA sequences




Using this information, the Patel group (MSKCC) obtained well-diffracting crys-
tals of TSN, crystallized in presence of either single stranded RNA sequence 5’-
(UG)3U(UG) or the tRNA dihydrouridine stem loop sequence (5’-GUAUAGUGGU-
UAGUAC). The structures were solved at 2.2 Å and 2.74 Å resolutions, respec-
tively, and revealed minor differences in the arrangement of octameric TSN, but no
bound RNA substrate in the expanded hollow interior of the closed-barrel struc-
tures, thus failing to improve on the previously reported human C3PO structure
[80].
9.1.2 Immunoprecipitations
In order to further probe the biochemical function of C3PO, I tried to identify in-
teracting proteins. Immunoprecipitation of either TSN or TSNAX, using anti-FLAG
or anti-TSNAX antibodies resulted only in the co-immunoprecipitation of the other
member of the complex, as indicated by the colloidal blue stain and WBs in Fig.
9.3. This was also observed in even mild salt conditions (150 mM NaCl) and
in the presence of the cell-permeable protein crosslinking agent DSP. Together,
these results suggest that C3PO does not form stable interactions with other pro-
tein factors, at least in our cellular system.
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Figure 9.3: C3PO co-immunoprecipitation. TSN or TSNAX were immunopre-
cipitated from HEK293 lysate after induction. (A) Colloidal blue staining of eluate.
(B) WB against HA tag, present on both TSN and TRAX. (C) WB against TSN
on the same membrane as (B). TSN runs at ∼25 KDa and TSNAX at ∼30 KDa.






To study the biological importance of C3PO in HEK293 cells, first I performed
siRNA-mediated transient knockdown of its members, followed by high-throughput
sequencing. Surprisingly, neither mRNA-seq or hydro-tRNAseq showed any re-
producible or statistically significant effect on the levels of tRNA or mRNA targets
of C3PO (data not shown). The same was true for smallRNA-sequencing, which
captures miRNAs and tRNA fragments. Therefore, transient depletion of C3PO
had no effect on the abundance of its RNA targets.
In light of these results, I generated TSN and TSNAX knockout cell lines by
CRISPR-Cas9-mediated genome editing. Since knockdowns did not have a global
pronounced effect on RNA levels, I reasoned that the depletion achieved by the
siRNA methodology (∼70% reduction in protein level) was not impactful enough to
result in an observable effect on global tRNA levels. Even though hydro-tRNAseq
analysis still pending, preliminary mRNA-seq analysis of multiple knockout clones




Figure 10.1: mRNA-seq analysis of TSN and TSNAX knockout clones. Scat-
terplot of mRNA expression values (in RPKMs). Parental HEK293 cell line always
corresponds to the x-axis. The knockout cell line and clone, as indicated on the
titles, corresponds to the y-axis.
10.2 Translational effects
Even though C3PO levels did not seem to have a detectable effect on RNA levels, I
reasoned that the complex could perhaps affect directly and specifically the trans-
lational efficiency of its 5’ UTR targets. In fact, the binding properties of C3PO
towards specific 5’ UTRs of some mRNAs reflect those of known translational fac-
tors, such as eIF3 [81], inasmuch as they include short (<50 nt) and single binding
sites (Fig. 10.2A,B), with GC-content significantly higher than randomly sampled,
size-matched sequences from the 5’ UTR background context (Fig. 10.2C), and
many predicted structural elements (Fig. 10.2D).
I observed that siRNA knockdowns of TSN led to increased translation of
mRNA targets identified by PAR-CLIP, including the genes HNRNPA0, GADD45a,
CJUN and JNK1 (Fig. 10.3). This did not seem to be the result of a confound-
ing cascade effect, due to the participation of many of the aforementioned genes
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Figure 10.2: C3PO 5’ UTR targets. (A) Length distribution of C3PO 5’ UTR clus-
ters. (B) Number of C3PO clusters in target genes. (C) GC content of C3PO 5’
UTR clusters (red), size-matched background sampled from all 5’ UTR sequences
(yellow), complete 5’ UTR sequences of C3PO targets (black) and all 5’ UTRs
(grey). Kolmogorov-Smirnov test p-values shown. (D) Predicted secondary struc-
tures of 5’ UTR targets of C3PO (and tRNA targets for comparison) - analysis
performed as in 3.5.
in shared signaling pathways, as another member of the pathway that was not a
C3PO target (ERK1/2) remained unaffected.
Nevertheless, such results should be taken with a grain of salt, given the high
inter-experimental variability across replicates of siRNA knockdowns, and also the
occasionally inaccurate quantification by WB densitometry.
For this reason, I decided to examine the proteome-wide effects of C3PO loss-
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Figure 10.3: Translation effects of TSN knockdown on mRNA targets. Top:
WB against 5’ UTR targets of C3PO upon two knockdown repicates (KD1, KD2)
and induction of expression of TSN. TUBB used as loading control and ERK1/2
as non-target control (not detected by PAR-CLIP). Bottom: densitometric analysis
of presented WBs.
of-function. I performed SILAC (stable isotope labeling by amino acids in cell
culture) followed by mass spectrometry, comparing C3PO knockout cell lines to
parental HEK293 cells. Rather surprisingly, again, there was not a single differen-
tially expressed protein in the overlap of three biological replicates carried out in




C3PO is a multimeric complex of the RNA binding protein TSN and the RNA en-
donuclease TSNAX. A plethora of functions have been assigned to this complex,
such as a role in the repair of DNA breaks, enhancement of RNAi activity, and
tRNA processing.
By performing PAR-CLIP I identified C3PO as a tRNA binding protein, and
showed that it did not bind to miRNAs or 3’ UTRs of mRNAs, arguing against a role
in RNAi. Except for tRNAs, the other main target of C3PO was 5’ UTRs, something
unusual for mRNA binding proteins apart from translation initiation factors.
In order to investigate the effects of C3PO in mRNA and tRNA stability, I
performed hydro-tRNAseq and small-RNAseq after depletion of C3PO by siRNA
knockdowns, and mRNAseq after both knockdowns and CRISPR-Cas9 knock-
outs. To my surprise, no significant effect was observed transcriptome-wide.
These results can be interpreted in two ways:
i) Since C3PO is an enzymatic complex, perhaps partial loss of function con-
ferred by siRNA knockdown is not sufficient to yield an observable phenotype,
at least under the tested experimental conditions. Given that hydro-tRNAseq
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analysis of the knockout clones is still pending, the possibility of an effect on
tRNAs, albeit improbable, cannot be ruled out.
ii) C3PO has an effect on translation rather than on mRNA or tRNA stability. This
hypothesis was reinforced initially by preliminary results, showing increased
protein levels of 5’ UTR targets identified, upon siRNA knockodown of TSN.
SILAC results, though, came in stark contrast as no significant proteome-wide
differences were observed after TSN or TSNAX knockout.
Trying to explain the lack of observable molecular phenotypes in the absence
of C3PO, one could invoke evolutionary mechanisms of redundancy. One hypoth-
esis could be that C3PO shares functions with another conserved nuclease (e.g.
RNase P), requiring the loss of both proteins/RNPs for a molecular phenotype to
arise. It would be interesting to create genetic models that allow combinatorial loss
of function of such candidates in either a transient or permanent fashion. Such an
approach would likely elucidate the interplay between C3PO and other factors and
unravel their epistatic relationships.
Alternatively, loss of C3PO may not result in dramatic steady-state defects,
but might sensitize cells to external toxic stimuli. In this case, one would need
to challenge C3PO-deplete cells with environmental or chemical stresses in order






C3PO PAR-CLIP was performed as described in section6.2 with the following dif-
ferences: Two RNase T1 steps were used. The crosslinked RNP was first trans-
ferred to a nitrocellulose membrane, followed by on-membrane proteinase K di-
gestion and RNA recovery from excised membrane pieces, in order to minimize
background contamination of highly abundant tRNAs.
12.2 Cleavage assays
In vitro cleavage assays were performed as described previously by our lab [77]
12.3 Immunoprecipitation
Immunoprecipitations were carried out using PAR-CLIP buffer conditions for ly-
sis and wash buffers (see section 6.2), with varying salt concentrations. DSP
crosslinking was performed as described previously [33].
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12.4 EMSAs, siRNA knockdowns, and SILAC
EMSAs and siRNA knockdowns were performed as described previously by our
lab [82]
12.5 CRISPR-Cas9 knockouts
CRISPR-Cas9-mediated genome editing was performed as described previously
[83]. Three small guide RNAs (sgRNAs) cognate to the coding region of TSN (5’-
GAGGTTTGTGTTGCAGCGCT, 5’-GTTGCAGCGCTTGGTCTTCT,
and 5’- TGAAATCCTTTCTCCCGATC) or TSNAX (5’- CATTTAAAGGCCAACAT-
CAC, 5’-TATAAGGATCAGGAGGGTTC, and 5’- GAGACTTGTGAAACTTAGTC).
PCR products were cloned using the Zero Blunt PCR Cloning Kit (Thermo Fisher
Scientific), six clones were sequenced per cell line to verify successful genome
editing, and three clones were kept and used in experiments.
12.6 mRNAseq analysis
Oligo(dT)-selected RNA was converted into cDNA for polyA mRNA-sequencing
using the Illumina TruSeq RNA Sample Preparation Kit v2 according to the in-
structions of the manufacturer and sequenced on an Illumina HiSeq 2500 platform
using 100 nt single-end sequencing. Analysis was performed using the Tuxedo
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